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ABSTRACT 
Somineni, Hari Krishna, M.S, Department of Pharmacology and Toxicology, Wright State 
University, 2013. Physical exercise training but not metformin attenuates albuminuria and 
shedding of ACE2 in type 2 diabetic db/db mice 
 
Angiotensin II (Ang II), a potent vasoconstrictor cleaved from Ang I, is responsible for renal 
damage in diabetes. Angiotensin converting enzyme 2 (ACE2) is highly expressed in the kidney 
and has been shown to be renoprotective by degrading Ang II to Ang-(1-7). A Disintegrin and 
Metalloproteinases (ADAMs) were recently identified as an ectodomain sheddases of 
transmembrane proteins. ADAM17 mediated shedding of renal ACE2 could contribute to the 
pathogenesis of diabetic nephropathy. In our previous study, rosiglitazone treatment normalized 
hyperglycemia and improved renal injury by preventing ACE2 shedding. The aim of this study is 
to test the hypothesis that improved glucose homeostasis with exercise and/or metformin 
attenuates albuminuria, renal ADAM17 protein and prevents shedding of ACE2 in db/db mice. 
Seven week old normal and db/db mice were subjected to physical exercise training and/or 
metformin treatment (150 mg/kg/day) for 10 weeks. Exercised mice ran on a mouse forced 
exercise walking wheel system for 1 hr a day for 7 days a week at a speed of 8 meters/minute. At 
juvenile stages (6 week old), db/db mice demonstrated higher levels of blood glucose, urinary 
albumin and ACE2 excretion. Urinary ACE2 is enzymatically active and 20 kDa shorter as 
demonstrated by immunoblotting. Renal ADAM17 and ACE2 protein levels were significantly 
upregulated in db/db mice compared to non-diabetic controls. In diabetic kidney, upregulated 
ADAM17 and ACE2 proteins co-localized in the tubular cortex. However, physical exercise 
training significantly attenuated blood glucose, urinary albumin and ACE2 excretion of db/db 
mice throughout the study period, whereas metformin treatment was effective in lowering 
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hyperglycemia only in the initial stages of diabetes. The increased renal ADAM17 protein levels 
in db/db diabetic mice were normalized by exercise training but not by metformin. In addition, 
exercise training reduced plasma triglycerides and enhanced insulin levels of db/db mice. The 
combination of exercise and metformin was effective against lowering plasma glucagon. Results 
demonstrated a significant association between blood glucose, urinary albumin, plasma insulin, 
glucagon and triglycerides with urinary ACE2 excretion. In conclusion, co-localization of 
ADAM17 with ACE2 suggests a possible interaction in diabetic kidney. Exercise training with 
or without metformin prevented shedding of renal ACE2 by attenuating ADAM17 protein. 
Elevated plasma insulin by exercise could be responsible for improved glucose homeostasis, at 
least in partial. Urinary ACE2 could serve as a prognostic tool in the progression of kidney 
damage and its attenuation by exercise may partially contribute to its renal protection.  
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1. INTRODUCTION 
Diabetes 
Diabetes mellitus is a group of metabolic disorders characterized by elevated blood glucose 
(hyperglycemia) due to absolute or relative deficiencies in insulin secretion and/or action 
(Orozco et al., 2008). This pandemic disease has reached epidemic proportions worldwide and 
approximately 285 million people were believed to be suffering with diabetes in 2010 and this 
figure is estimated to reach 439 million by 2030 (Tramonti & Kanwar, 2012). Recent reports 
suggest that 26 million people in the United States are suffering from diabetes (Zhang, 2011) and 
this economic burden is expected to reach $490 billion by 2030 (Farag & Gaballa, 2011).  
Classification of diabetes 
The disease diabetes mellitus can be classified into four types as per the new classification 
system: type 1, type 2, gestational diabetes and other specific types (American Diabetes 
Association, 2013a). Type 1 diabetes mellitus or juvenile diabetes is characterized by beta cell 
destruction caused by an autoimmune process, usually leading to absolute deficiency of insulin 
secretion. The onset is usually acute, developing over a period of a few days to weeks. Type 2 
diabetes mellitus is characterized by insulin resistance in peripheral tissue and defects in insulin 
secretion. Insulin resistance and hyperinsulinemia eventually lead to impaired glucose tolerance 
(American Diabetes Association, 2013b). Type 2 diabetes accounts for at least 90% of all cases 
of diabetes and is highly associated with a family history of diabetes, older age, obesity and lack 
of exercise. Gestational diabetes is a type of diabetes with high blood glucose levels during 
pregnancy. Gestational diabetes may eventually lead to type 2 diabetics (Massi-Benedetti, 2002). 
Other types of diabetes includes persons with genetic defects of beta-cell function also called 
MODY or maturity-onset diabetes in youth, persons with pancreatic dysfunction caused by 
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drugs, chemicals or infections, persons with diseases of the exocrine pancreas, such as 
pancreatitis, cystic fibrosis, trauma/pancreatectomy, and other genetic syndromes like Down’s 
syndrome, Klinefelter’s syndrome and Turner’s syndrome (American Diabetes Association, 
2013b). 
Diagnosis of diabetes 
Based on the current criteria, diagnosis of diabetes is made, if any one of the following 
conditions is met: 1. Fasting (at least 8 hours) plasma glucose ≥ 126 mg/dL. 2. Two-hour plasma 
glucose ≥ 200 mg/dL, in 75 g oral glucose tolerance test (American Diabetes Association, 2010). 
3. Glycosylated hemoglobin A1C (HbA1c) ≥ 6.5% (Alberti & Zimmet, 1998; American Diabetes 
Association, 2013a). In addition to these, there is an intermediate stage between the 
normoglycemia and diabetes known as prediabetic stage where impaired fasting glucose (the 
fasting glucose levels range from 110 mg/dL to 126 mg/dL) and impaired glucose tolerance are 
seen. However, mechanisms resulting in hyperglycemia vary from patient to patient, urging the 
need of developing new diagnostic approaches, prevention strategies, and therapeutic 
interventions.  
Complications of diabetes 
Chronic hyperglycemia results in the dysfunction of various organs such as the kidney, heart, 
nerves, eyes, and blood vessels. Complications associated with diabetes play an important role in 
determining the quality of life of patients. Diabetic complications could be divided into micro 
and macrovascular dysfunctions. Microvascular complications of diabetes include nephropathy, 
retinopathy and neuropathy (Massi-Benedetti, 2002). Macrovascular complications include 
cardiovascular and sexual dysfunction (Brownlee, 2005). Cardiovascular disease is a major 
contributor of morbidity and mortality in diabetic patients. However this condition is also known 
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to coexist with hypertension and dyslipidemia (Levey et al., 2009; Slinin et al., 2012; American 
Diabetes Association, 2013b).  
Diabetic nephropathy  
Diabetic nephropathy is one of the major microvascular complications of diabetes which 
eventually manifests into end-stage renal disease (ESRD) (Jim et al., 2012; Futrakul et al., 2006; 
Jawa et al., 2006). One-third of the diabetic population is prone to develop nephropathy and it 
represents the major cause of morbidity and mortality (Cooper, 1998). Diabetic nephropathy is 
classically defined by albuminuria and impaired renal function such as abnormal serum 
creatinine, creatinine clearance and glomerular filtration rate. This is predominantly seen in 
African Americans, Asians, and Native Americans (Young et al., 2003). In diabetes, high 
glucose-induced activated renin angiotensin system (RAS) and glomerular hyperfiltration are 
considered to be the primary causes underlying this implication (O'Bryan & Hostetter, 1997; 
Hostetter, 2003). Increased content of renal Ang II results in the depletion of glomerular nephrin 
and increased glomerular pore size (Giacchetti et al., 2005; Bichu et al., 2009), which makes 
several proteins to pass through easily. Polyol compounds generated from the excess glucose, 
glycation of tissue proteins, and generation of reactive oxygen species (ROS) by hyperglycemia 
are the other possible mechanisms implicated in tissue damage (Aronson, 2008; Shi et al., 2013). 
Further, excess glucose in diabetes reacts with several proteins and results in the formation of 
advanced glycation end-products (AGEs). AGEs mediate renal injury by producing ROS, 
activating protein kinase C (PKC), mitogen-activated protein kinase (MAPK) and nuclear factor 
kappa-light-chain-enhancer of activated B cell (NF-κB) pathways (Cooper, 2004). In addition, 
AGEs acts through AGE receptors (RAGE) and promotes collagen deposition, inflammation, and 
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growth of extracellular matrix proteins ultimately leading to tissue fibrosis (Cooper, 2004). 
Further, ROS cause podocyte apoptosis, thus initiating kidney damage (Susztak et al., 2006).  
Clinical manifestations of nephropathy include albuminuria (Gall et al., 1997), hypertension, 
impaired renal function (Tan et al., 2010) and a high incidence of cardiovascular morbidity and 
mortality (Wang et al., 1996). Diabetic nephropathy is generally characterized by mesangial 
matrix expansion, glomerular thickening of basement membrane, and proteinuria which are 
associated with chronic renal failure (Giunti et al., 2006; Forbes & Cooper, 2013). Previously it 
was believed that kidney disease is unidirectional. However, recent research reported that early 
therapeutic interventions may prevent or delay progression to ESRD. The biggest challenge for 
healthcare professionals is accurate and early detection of diabetic kidney disease. According to 
the recent guidelines from the American Diabetic Association, kidney disease can be categorized 
into 5 stages based on the glomerular filtration rate (Levey et al., 2009; Slinin et al., 2012; 
American Diabetes Association, 2013b).  
Table 1: Stages of CKD 
Stage Description 
GFR (mL/min/1.73 m
2 
body surface area) 
1 Slight kidney damage with normal or increased filtration More than 90 
2 Mild decrease in kidney function 60 to 89 
3 Moderate decrease in kidney function 30 to 59 
4 Severe decrease in kidney function 15 to 29 
5 Kidney failure Less than 15 (or dialysis) 
 
Even though considerable scientific effort has been made to identify patients at risk for the 
development of diabetic nephropathy, very little was achieved so far (Susztak & Bottinger, 2006; 
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Sharma et al., 2005). Appreciably, microalbuminuria is the only noninvasive technique available 
for the diagnosis of diabetic nephropathy. However, onset of diabetes is difficult to ascertain and 
so many patients diagnosed with high blood glucose already have microalbuminuria (Lee, 2005). 
Moreover, recent clinical studies questioned the reliability of albuminuria in anticipating the 
progression and prevention of ESRD (de Galan et al., 2009). Therefore, there is an urging need 
for sensitive and specific biomarkers for better prediction of diabetic nephropathy. A substantial 
amount of evidence demonstrates that strict glycemic control (Tan et al., 2010) as well as 
blockade of RAS provides renoprotection (Lewis et al., 1993; Maschio et al., 1996; Hostetter, 
2003). 
The renin angiotensin system (RAS) 
RAS is an endocrine or hormone system that regulates blood pressure, fluid balance, and tissue 
repair. RAS is found not only in the plasma but also in tissues like kidney, heart, vasculature, 
brain, retina, liver, pancreas, reproductive system, lymphatic and adipose tissue (Danser & 
Schalekamp, 1996; Paul et al., 2006; Baltatu et al., 2000; Bader et al., 2001; Bataller et al., 2003; 
Lau et al., 2004). When the blood volume drops, juxtaglomerular cells in the kidney secrete renin 
into the circulation. Renin plays a crucial role in RAS due to its rate-limiting activity on the 
precursor angiotensinogen (Weber, 2001; Zaman et al., 2002). The system begins by the release 
of angiotensinogen into circulation by the liver. An enzyme renin converts angiotensinogen to an 
inactive decapeptide angiotensin (Ang) I. Ang I is further converted to Ang II by angiotensin 
converting enzyme (ACE), which is predominantly found in the pulmonary circulation. 
However, ACE is also produced in the vascular endothelium of many tissues including kidneys, 
adrenal glands, brain and heart. Ang II thus formed act through Ang II type 1 receptor (AT1R) 
and regulate several activities such as vasoconstriction, sodium retention, aldosterone release, 
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hyperplasia, and hypertrophy. Further transformation of Ang II is carried out by angiotensin 
converting enzyme 2 (ACE2), a recently discovered homologue of ACE. ACE2, a monocarboxy 
peptidase degrades the octapeptide Ang II to a heptapeptide Ang-(1-7). Alterations within the 
RAS are considered to play an important role in the pathogenesis of diabetic complications, 
particularly diabetic renal disease and hypertension (Burnier & Zanchi, 2006). 
Angiotensin II (Ang II) 
Ang II is a potent vasoactive peptide generated by the actions of a dipeptidyl carboxypeptidase, 
ACE on Ang I. It is widely distributed in the kidney, heart, brain, adipose tissue, gonads, 
pancreas, and plasma (Nielsen et al., 2000; Navar & Nishiyama, 2004; Brewster & Perazella, 
2004). Ang II is important in regulating salt, water, and vascular homeostasis (Belova, 2000). 
Being a positive regulator of RAS, Ang II is believed to play an important role in triggering 
hypertension, inflammation, oxidative stress and aldosterone release from adrenal glands 
(Schmidt-Ott et al., 2000; Mehta & Griendling, 2007). Moreover, it is implicated to have direct 
actions in the pathophysiology of renal and cardiovascular diseases such as cardiac hypertrophy 
and remodeling, heart failure, vascular thickening, atherosclerosis, and glomerulosclerosis in 
humans. Interestingly, concentrations of renal Ang II are approximately 1000 fold higher 
compared to their circulatory levels, suggesting the existence of an intrarenal RAS (Seikaly et 
al., 1990). However, in contrast to this, several reports demonstrate circulatory Ang II as a source 
Ang II in the kidney. Despite of these discrepancies, Ang II is implicated to play a crucial role in 
glomerular injury by several mechanisms. Most of the actions of Ang II are mediated by G-
protein dependent pathways. However, activation of nicotinamide-adenine dinucleotide 
phosphate (NADPH) and generation of reactive oxygen species by Ang II are considered as the 
important mechanisms underlying inflammation and fibrosis (Mehta & Griendling, 2007). 
7 
 
Ang II receptors 
Physiological actions of Ang II are mediated by the G-protein coupled receptors Ang II type 1 
(AT1R) and Angiotensin II type 2 (AT2R) (Schmidt-Ott et al., 2000; Mehta & Griendling, 
2007). Most of the known physiological and pathological actions of Ang II are mediated by 
AT1R (Schmidt-Ott et al., 2000; Mehta & Griendling, 2007) and hence they are considered 
crucial. The AT1R is a 359 amino acid protein belonging to the seven-membrane superfamily of 
G protein-coupled receptors and is predominantly distributed in the kidney, heart, liver, adrenals, 
brain, lung, and vasculature. Two isoforms, AT1A and AT1B sharing 95% amino acid sequence 
similarity with no differences in functionality and pharmacology were reported in rodents. 
However, only AT1A is characterized in humans (Crowley et al., 2007). AT1R receptors are up-
regulated by conditions that increase Ang II such as dehydration and sodium deficiency (Barth & 
Gerstberger, 1999; Sanvitto et al., 1997; Chen et al., 2003), indicating that expression of AT1R is 
affected by its agonist Ang II. db/db mice have high levels of circulating Ang II (Senador et al., 
2009). So it is plausible that high expression of AT1R in response to high-circulating Ang II 
could lead to diabetes related complications in db/db diabetic mice. AT1R after getting activated 
by the agonist, Ang II, couple to Gαq/11, Gα12/13, Gβy complexes (Ushio-Fukai et al., 1998) and 
results in the activation of protein kinase C (PKC) and the extracellular signal regulated kinase 
(ERK) pathway. These mechanisms are implicated in the maintenance of contraction as well as 
cellular growth. Further, it is also known to activate some of the downstream effectors including 
phospholipase C (PLC), phospholipase A2 (PLA2) and phospholipase D (PLD) (Ushio-Fukai et 
al., 1999).  
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Angiotensin converting enzyme 2 (ACE2) 
ACE2 is a membrane-bound, monocarboxy peptidase sharing 40% homology with ACE. 
However, it is also reported to exist as a soluble form (Donoghue et al., 2000; Feng et al., 2008). 
Although it exhibits sequential homology and similarity with ACE, ACE2 has different 
biochemical activities and is not arrested by conventional ACE inhibitors like captopril and 
lisinopril (Tipnis et al., 2000). Initially, ACE2 was thought to be restricted to human kidney, 
heart, and testis (Donoghue et al., 2000). Later, it has been characterized in various other tissues 
like brain, liver, lungs, adipose tissue, pancreas, and retina (Danser & Schalekamp, 1996; Paul et 
al., 2006; Baltatu et al., 2000; Bader et al., 2001; Bataller et al., 2003; Lau et al., 2004). ACE2 
cleaves a single carboxy residue from Ang I and Ang II and generates Ang-(1-9) and Ang-(1-7) 
respectively. ACE2 is conceded to play a counter-regulatory role in RAS and consequently many 
studies demonstrated its involvement in cardiovascular diseases (Tipnis et al., 2000; Wysocki et 
al., 2006) as discussed below.  
Renoprotection of ACE2 
ACE2 is implicated to have positive effects in renal and cardiovascular disease (Monteiro et al., 
2008; Alghamri et al., 2012; Wysocki et al., 2006). Distribution of ACE2 is 20-fold higher in the 
kidney compared to heart and is predominantly localized in the proximal tubules (Tikellis et al., 
2003). ACE2 is shown to be renoprotective by degrading Ang II to Ang-(1-7), a biologically 
active peptide that contravene the negative effects of Ang II by interacting with the G protein-
coupled receptor Mas (Tipnis et al., 2000; Passos-Silva et al., 2013).  
A study conducted on STZ-induced diabetic rodent models reported reduced ACE2 mRNA and 
protein levels in diabetic conditions (Tikellis et al., 2003). Further, a study conducted in STZ-
induced diabetic rats by Moon et al. demonstrated a negative correlation between glomerular 
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ACE2 protein and proteinuria (Moon et al., 2008). Decreased glomerular ACE2 was associated 
with enhanced albuminuria in db/db mice (Ye et al., 2006). Moreover, pharmacological 
inhibition of ACE2 in STZ diabetic mice resulted in increased albuminuria and declined renal 
functioning (Soler et al., 2007), whereas its deletion aggravated albumin excretion in the urine of 
an Akita mouse model of type 1 diabetes (Wong et al., 2007) which is reversed by the 
administration of human recombinant ACE2 (Oudit et al., 2010). Furthermore, overexpression of 
ACE2 in diabetic rodent models has been reported to ameliorate diabetic nephropathy (Liu et al., 
2011; Nadarajah et al., 2012). In addition to the animal models, a study conducted on human 
subject’s demonstrated downregulation of renal ACE2 protein expression in diabetic patients 
with nephropathy (Reich et al., 2008).  
Urinary markers for the diagnosis of renal injury 
Urine is the most important tool for identifying biomarkers in non-invasive fashion 
(Thongboonkerd, 2008). Urine testing for biomarkers could substitute renal biopsy as safe and 
painless alternative. Common causes for urinary markers in diabetic nephropathy are kidney 
damage (glomerular injury), oxidative stress, inflammation, and vascular damage (Matheson et 
al., 2010). Enzymes and low-molecular weight proteins, characteristic of tubular and glomerular 
damage, are used as potential markers (De Carvalho et al., 2011).  
Albuminuria 
Albuminuria is a widely accepted and well-established marker for diabetic nephropathy. 
Microalbuminuria is a condition where urinary albumin excretion ranges from 30 to 300 mg/day 
and is considered as a first sign of renal impairment which is widely used as a clinical tool for 
the diagnosis of early nephropathy (Remuzzi et al., 2002; Barratt & Topham, 2007). However, 
microalbuminuria is not detectable by a standard urine dipstick test (Saeed et al., 2012; Barratt & 
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Topham, 2007). If the urinary albumin levels exceed 300 mg/day, condition is known as 
macroalbuminuria, overt proteinuria, or dipstick-positive proteinuria (Matheson et al., 2010; 
Saeed et al., 2012), which is evident after a significant kidney damage (Levey et al., 2009; 
Barratt & Topham, 2007). Even though albuminuria has been considered as a potent non-
invasive biomarker, it is seen only after a significant glomerular damage (Barratt & Topham, 
2007). Hence, there is a need for more specific, and reliable biomarker to predict diabetic 
nephropathy in early stages. In addition, ADVANCE (Action in Diabetes and Vascular disease: 
PreterAx and DiamicroN-MR Controlled Evaluation) study reported that treating type 2 diabetic 
patients with pharmacological interventions (perindopril/indapamide) normalized albuminuria; 
however, they developed ESRD (de Galan et al., 2009). Continuing in this vein, due to its wide 
range (30 to 300 mg/day), recent clinical studies questioned the reliability of albuminuria in 
anticipating the progression and prevention of ESRD (de Galan et al., 2009; Haller et al., 2011). 
Therefore, there is a need for a more sensitive and specific marker for better prediction of 
diabetic nephropathy.  
Recent discoveries in the field of biomarkers  
For instance, N-acetyl β-glucosaminidase is a lysosomal enzyme derived from proximal tubular 
cells that are not filtered by the kidney under normal circumstances. Its excretion increases in 
circumstances that cause tubular injury (Basturk et al., 2006). Urinary microvesicle-bound 
dipeptidyl peptidase-IV, a membrane-associated peptidase enzyme secreted from the tubular 
epithelial cells, can be used as an early marker of renal damage (Sun et al., 2012). In addition, 
decreased podocyte number (Zheng et al., 2011) as well as stress-induced shedding of 
adiponectin hormone (Kadowaki & Yamauchi, 2005) in urine can be used to characterize the 
onset of diabetic nephropathy. Increased concentrations of liver-type fatty acid-binding protein 
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(Nielsen et al., 2010) and pigment epithelium-derived factor (PEDF) (Chen et al., 2010) in urine 
can be used to predict the development of nephropathy in type 1 and type 2 diabetic patients 
respectively.   
Urinary RAS components as biomarkers 
In recent years, Kobori and his associates have shown angiotensinogen, component of RAS in 
urine that could be used as a marker for intrarenal RAS status in STZ-induced diabetic mice as 
well as patients with hypertension and chronic kidney disease (CKD) (Kobori et al., 2009; 
Kobori & Urushihara, 2013; Kamiyama et al., 2012). Continuing in this vein, it is reported that 
urinary angiotensinogen precedes albuminuria and hence could be used as an early biomarker for 
diabetic nephropathy in type 1 diabetic patients (Saito et al., 2009). Apart from angiotensinogen, 
another component of RAS, ACE has been validated in the urine. The N-domain isoform of ACE 
observed at 90 kDa is associated with hypertension and the absence of this isoform was 
associated with normal blood pressure levels in human subjects suggesting that the N-domain 
isoform of ACE could serve as a urinary biomarker (Maluf-Meiken et al., 2012; Casarini et al., 
2001). 
ADAM17  
A Disintegrin and Metalloproteases (ADAMs) are zinc-dependent, multidomain transmembrane 
proteins belonging to the adamalysin family of metalloproteinases (White, 2003). 
Metalloprotease domains of this membrane-anchored proteinase mediate ectodomain shedding, 
resulting in proteolytic release of various transmembrane proteins, growth factors and cytokines 
and the disintegrin domains are cysteine-rich involved in adhesive activities (Wolfsberg et al., 
1993; Blobel et al., 1992). ADAM10 and ADAM17 also known as tumor necrosis factor-α-
converting enzyme (TACE) are the most active sheddases of this family. ADAM17, sharing 
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close sequence similarities and potential structural features with ADAM10, was addressed to 
play a crucial role in various activities among all the ADAMs (Gooz, 2010). 
ADAM17 is a cell surface protein found in many tissues like the kidney, heart, brain, and 
skeletal muscle (Black et al., 1997). Previous studies demonstrated the role of ADAM17 in a 
broad spectrum of diseases such as cancer, inflammation and alzheimer’s disease apart from 
diabetes (Kaneko et al., 2011; Gooz, 2010; Federici et al., 2005). A recent study using type 1 
diabetic mouse model demonstrated that hyperglycemia results in the activation of renal 
ADAM17 (Ford et al., 2013). Alternatively, a study conducted on Ang II-infused mice 
demonstrated increased ADAM17 protein levels, suggesting the role of Ang II in activation and 
enhancement of ADAM17 (Lautrette et al., 2005). ADAM17 became a prime target for 
developing therapies due to its ability to shed a large variety of substrates, including ACE2. 
Lambert et al. demonstrated the role of ADAM17 in ectodomain shedding of ACE2 from stably 
transfected HEK293 cells and endogenously expressing Huh7 cells in vitro (Lambert et al., 
2005). A Study conducted on CHO cells established the site of action of ADAM17 on ACE2 as 
Arg708_Ser709 bond (Lai et al., 2011). Further, Jia et al. showed the involvement of ADAM17 
in ectodomain shedding of ACE2 in human airway epithelia (Jia et al., 2009). However, the 
biological importance of shedding events mediated by ADAM17 in vivo has not been fully 
elucidated. Due to its involvement in various deleterious activities, ADAM17 became a prime 
target for developing therapies. Biological inhibition of ADAM17 has been witnessed to 
ameliorate insulin resistance in obese mice by lowering tumor necrosis factor alpha (TNF-α) 
production from its precursor (Kaneko et al., 2011). Administration of WTACE2, a 
pharmacological inhibitor for ADAM17, is implicated to exert beneficial effects in chronic 
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kidney injury by attenuating glomerular and tubular lesions and interstitial fibrosis (Lautrette et 
al., 2005).  
On the other hand, excitation of several cell signaling pathways resulting in dimeric to 
monomeric shift of ADAM17 was associated with increased ADAM17 and decreased tissue 
inhibitor of metalloproteinase 3 (Timp3), suggesting Timp3 as an endogenous inhibitor of 
ADAM17 (Xu et al., 2012). Continuing in this vein, recent studies suggest that deficiency of 
Timp3 results in increased ADAM17 activity and TNF-α production leading to diabetes in 
heterozygous insulin receptor mutant mice (Federici et al., 2005) and exacerbating diabetic 
nephropathy in the Akita, type 1 diabetic mouse model (Basu et al., 2012). 
Benefits of physical exercise training in diabetes 
Lifestyle intervention program is a cornerstone therapy for preventing (Knowler et al., 2002; 
Tuomilehto et al., 2001) or managing patients with type 2 diabetes (Sigal et al., 2006). 
Retrospective clinical trials validated exercise training as an important non-pharmacological 
strategy to prevent diabetes and obesity (Pan et al., 1997). However, the American Diabetes 
Association (ADA) and European Association for the study of diabetes (EASD) recommended 
initiation of a pharmacological treatment concurrently with lifestyle intervention to gain tight 
control over diabetes and related complications (Rhee et al., 2010; Nathan et al., 2009; 2012). 
From the perspectives of efficacy and economy, the Diabetes Prevention Program (DPP) and its 
Outcomes Study (DPPOS) demonstrated lifestyle intervention as a cost-effective strategy in 
preventing diabetes especially type 2 and reduced diabetes incidence by 58% in high risk patients 
(Knowler et al., 2002; Tuomilehto et al., 2001; Fradkin et al., 2012). Furthermore, a randomized 
clinical trial conducted in individuals with impaired glucose tolerance reported that interventions 
with exercise, diet, and both exercise and diet were associated with 46%, 31%, and 42% 
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reduction in the incidence of diabetes respectively (Pan et al., 1997), suggesting the efficacy of 
exercise alone in preventing type 2 diabetes.  
150 minutes per week of moderate intensity exercise or 90 minutes per week of vigorous 
intensity exercise or an equivalent combination of the two is recommended to achieve 
therapeutic benefits in many chronic diseases, particularly type 2 diabetes (U.S.Department of 
Health and Human Services, 2008; American Diabetes Association, 2013a). Exercise is shown to 
reduce the incidence of diabetes by 46% in patients with impaired glucose tolerance, which is an 
intermediate stage between normal glucose tolerance and the disease diabetes. In addition, 
follow-up of the Finnish diabetes prevention study demonstrated reduced incidence of type 2 
diabetes even 3 years after termination of the intervention (Lindstrom et al., 2006). Exercise 
training has been shown to attenuate hepatic glucose production (Minuk et al., 1981) and 
accentuate peripheral glucose utilization in human subjects by enhancing insulin mediated 
glucose transported type 4 (GLUT-4) translocation or by increasing 5’ adenosine 
monophosphate-activated protein kinase (AMPK) α2 activity (insulin independent) (Ivy, 1997; 
Musi et al., 2001). Physical exercise is known to enhance insulin-stimulated glucose disposal via 
several mechanisms such as increasing insulin sensitivity by changing the body composition 
(Yki-Jarvinen & Koivisto, 1983), stimulating muscle blood flow (Yki-Jarvinen & Koivisto, 
1983) and GLUT-4 protein levels (Rodnick et al., 1990; Yki-Jarvinen & Koivisto, 1983), 
ameliorating insulin resistance, and glucose tolerance (Ivy, 1997). In a recent study on high-fat-
fed mice, exercise has been shown to ameliorate glucose homeostasis and obesity via 
upregulation of plasma irisin, a hormone that stimulates browning and uncoupling protein 1 
(UCP1) expression (Bostrom et al., 2012). In addition, moderate intensity exercise is associated 
with decreased inflammatory markers (interleukin-6; IL-6, tumor necrosis factor alpha; TNF 
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alpha and C-reactive protein; CRP) in healthy, older subjects (Colbert et al., 2004). Exercise 
training is implicated to prevent diabetic complications by lowering blood sugars, enhancing 
insulin sensitivity, and improving lipid profile (Arakawa, 1993; Zinman & Vranic, 1985).  
Effects of exercise training on RAS 
Hyperglycemia activates RAS and reactive oxygen species (ROS) and thus plays an important 
role in triggering inflammation. Several studies on animal models validated the beneficiary role 
of exercise on renal, brain, and cardiac RAS components (Pereira et al., 2009; Fernandes et al., 
2011). Exercise training has been shown to degrade AT1R and Ang II protein levels and enhance 
ACE2 protein expression in the kidney of STZ-induced diabetic mice (Ciampone et al., 2011; 
Cunha et al., 2010). Regarding cardiac RAS, exercise training has been demonstrated to 
attenuate ACE and Ang II proteins and upregulate ACE2, Ang-(1-7) and AT2R protein levels in 
the heart of normotensive wistar rats (Fernandes et al., 2011). In addition, it is reported to 
enhance ACE2 protein expression in the brain of rabbits with chronic heart failure (Kar et al., 
2010).  
Renoprotective role of exercise training 
Although several randomized clinical studies validated the beneficiary effects of exercise with or 
without diet restriction on the primary disease diabetes, effects of these interventions on the 
complications associated with it have not been extensively investigated. However, a very few 
studies addressed the renoprotective actions of exercise using animal models of diabetic 
nephropathy (Agarwal et al., 2012). Physical exercise is demonstrated to attenuate albuminuria, 
proteinuria, and glomerular sclerosis and maintain podocyte number in animal models of 
nephropathy (Kohzuki et al., 2001; Tufescu et al., 2008; Ishikawa et al., 2012). In addition, 
exercise training is unveiled to mitigate renal caspase-3 activity, mesangial matrix expansion and 
16 
 
tubulointerstitial fibrosis (Ghosh et al., 2009). Evidence suggests that exercise training improves 
renal injury in partial by lowering inflammation (Kasapis & Thompson, 2005; Ishikawa et al., 
2012), oxidative stress (Ishikawa et al., 2012) and hypertension (Cardoso et al., 2012). 
Continuing in this vein, Boor et al. demonstrated the renoprotective effects of exercise could be 
partially mediated by alleviating plasma and renal advanced glycation end-products (Boor et al., 
2009). However, clinical studies that investigated the beneficiary effects of exercise in chronic 
kidney disease are limited.  
Metformin 
Metformin is increasingly being used for the management of type 2 diabetes, especially after the 
adverse effects of thiazolidinediones became known. Retrospective clinical trials have shown 
metformin as the first line oral, anti-diabetic drug in treating type 2 diabetes (Rocha et al., 2012). 
Considering efficacy and its potential for cost-savings, Diabetes Prevention Program (DPP) and 
its Outcomes Study (DPPOS) demonstrated metformin as a marginally cost-saving strategy in 
preventing type 2 diabetes and was reported to reduce the incidence of diabetes by 31% in high 
risk patients (Knowler et al., 2002; Tuomilehto et al., 2001). Metformin acts by stimulating 
AMPK, resulting in the attenuation of hepatic glucose production and enhancement of peripheral 
glucose uptake (Scarpello & Howlett, 2008; Zhou et al., 2001). Upregulation of GLUT-1 and 
GLUT-4 plasma membrane concentrations were also implicated in the enhanced peripheral 
glucose uptake by metformin (Musi et al., 2002). However, metformin is potentially known to 
induce lactic acidosis.  
Renoprotective role of metformin 
A study conducted by UKPDS addressed that intensive glucose control with metformin, 
significantly reduced the risk of diabetes related outcomes in over-weight type 2 diabetic 
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patients. In particular, short-term administration of metformin attenuated albuminuria in type 2 
diabetic patients (Amador-Licona et al., 2000). A study conducted by Zapecka et al 
demonstrated the renoprotective role of metformin could be mediated by reducing circulating 
amylin levels in type 2 diabetic patients (Zapecka-Dubno et al., 1999). Amylin is a peptide 
secreted by pancreatic beta cells, whose deposition in the kidney results in the severity of 
nephropathy (Gong et al., 2007). In addition, treatment with metformin significantly reduced 
plasma cholesterol and triglycerides (Amador-Licona et al., 2000) in type 2 diabetic patients, 
indicating the renoprotective efficacy of metformin, as hypercholesterolemia and 
hypertriglyceridemia were known to be associated with reduced kidney function even in 
nondiabetic healthy subjects (Maschio et al., 1989). As an extension, recent studies corroborated 
the renoprotective role of metformin in patients with CKD (Robinson-Cohen et al., 2009; Duong 
et al., 2012).  
 
The incidence of type 2 diabetes and associated ravages were constantly increasing worldwide. 
Based on the retrospective clinical trials, first line recommendation for the prevention or 
management of type 2 diabetes is the combination of lifestyle (exercise training coupled with 
diet restriction to lose body weight) and metformin interventions. Alternatively, a study 
conducted by Pan et al. demonstrated that exercise alone is as effective as exercise plus diet in 
diabetics. However, no study was done until now in human subjects using the combination of 
exercise training and metformin treatment. In addition, effects of these interventions on the 
complications associated with diabetes are still under investigation. Therefore, in the current 
study, we investigated the individual as well as combined effects of exercise and metformin 
18 
 
during the early and late stages of diabetes and associated microvascular complications, diabetic 
nephropathy using type 2 diabetic mouse model. 
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2. HYPOTHESIS AND SPECIFIC AIMS 
Hypothesis 
Hyperglycemia induced shedding of renal ACE2 via ADAM17 is associated with the renal injury 
of db/db mice. Improved glucose homeostasis with exercise and/or metformin prevents shedding 
of renal ACE2 and ameliorates renal injury in db/db mice. 
Specific aims 
1. To test the hypothesis that, short-term physical exercise training and/or metformin 
treatment is associated with improved glucose homeostasis and decreased urinary 
albumin and ACE2 excretion of db/db mice.  
2. To test the hypothesis that, long-term physical exercise training and/or metformin 
treatment is associated with improved glucose homeostasis and decreased urinary 
albumin and ACE2 excretion of db/db mice.  
3. To test the hypothesis that, urinary ACE2 could be used as a biomarker for diabetic 
nephropathy and as a surrogate marker of diabetes. 
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3. MATERIALS AND METHODS 
Animals 
Five-week-old male db/db (BKS.Cgm +/+ Lepr
db
/J) mice and their age-matched
 
non-diabetic 
littermates (db/m) were purchased from Jackson Laboratories (Bar Harbor, ME, USA). The 
genetically diabetic mouse (db/db) has a mutation on the chromosome 4 that inhibits the 
expression of leptin receptor (Hummel et al., 1966). The syndrome of type 2 diabetes mellitus in 
db/db mice is similar to adult humans and is characterized by hyperinsulinemia, obesity, and 
progressive hyperglycemia. Animals were housed in standard cages at 22C under a 12-hour 
light/12-hour dark cycle with ad libitum access to water and standard mouse chow. Wright State 
University Animal Care and Use Committee approved all experimental protocols. 
Intervention with exercise and/or metformin 
Seven-week-old mice were randomly assigned to 8 different groups: (1) Non-diabetic control 
(Normal) mice receiving regular water; (2) Normal mice receiving metformin in water (150 
mg/kg/day; Spectrum laboratories, USA); (3) Normal mice receiving regular water and 
exercising daily (1 hour per day at a moderate intensity for 10 weeks); (4) Normal mice receiving 
metformin water and exercising daily; (5) db/db group receiving regular water; (6) db/db group 
receiving metformin water (150 mg/kg/day); (7) db/db group receiving regular water exercising 
daily and (8) db/db group receiving metformin water and exercising daily. Exercised mice ran on 
a mouse forced exercise walking wheel system (Lafayette Instrument, Lafayette, IN, USA). The 
mice began wheel-running for 1 hour a day, 7 days a week. Initial speed was set at 4 
meters/minute and daily increased by 1 meter/minute and reached 8 meters/minute by the end of 
first week of training. In subsequent weeks, the mice were run for 1 hour a day at 8 
meters/minute. Mice were run during the end of their dark cycle. All mice were monitored 
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weekly for blood glucose, body weight, food intake, water intake, and urine output. After 10 
weeks of treatment, mice were euthanized by decapitation and trunk blood was collected in ice-
chilled heparinized tubes. Plasma was immediately separated, centrifuged at 10,000 x g for 10 
minutes at 4° C and stored at -80° C. Kidneys were collected in dry ice and stored at -80° C. 
Blood glucose measurement 
FreeStyle® Blood Glucose Test Strips & FreeStyle Lite® Blood Glucose Monitoring System 
117 (Abbott Diabetes Care Inc, CA, USA) were used to measure blood glucose levels. A small 
cut was made on the tip of the tail vein to collect a drop of blood. Values were expressed in 
mg/dL.  
Glucose tolerance test 
An intra-peritoneal glucose tolerance test was performed in control normal, control db/db mice, 
and db/db mice subjected to exercise and/or metformin. Mice were fasted overnight for 16 hours 
and blood samples were collected from a cut made at the tip of the tail at 0, 30, 60, 90 and 120 
minutes after a glucose load (I.P. injection of glucose in an aqueous solution, 1.5 g/kg). Samples 
were diluted in 300 µl water and 25 µl lysis buffer. Glucose concentration was determined using 
glucose oxidase/peroxidase reagent kit (Sigma, St. Louis, MO). 
Body composition measurement 
Body composition was measured using an ECHO MRI absolute body composition analyzer 
(Houston, TX, USA). Body weight of the mouse was determined. Instrument was calibrated and 
the mouse was placed in a transparent plastic cylinder and held in position with a plastic plunger 
to avoid any movements. This setup was placed inside the instrument and the measurements 
were taken.  
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Urine collection 
For 24-hour urine collection, mice were housed individually in metabolic cages with a free 
access to food and water. A total of 20 µl of protease inhibitor (Roche Diagnostics, IN, USA) 
was used in each tube while collecting the urine. First collection was done at the end of the 12
th
 
hour and samples were stored at 4°C until the second collection. After the second collection at 
the 24
th
 hour, samples were centrifuged at 10,000 x g for 3 minutes at 4°C. Then the supernatant 
was separated from the debris. Final volumes were recorded, aliquoted accordingly and stored at 
-80°C  
Urinary albumin assay 
To monitor kidney function, quantitative estimation of urinary albumin was performed using a 
kit purchased from Bethyl Laboratories (Montgomery, TX, USA). Standards were diluted 
according to the kit’s protocol and samples (2 µl sample + 998 µl sample conjugate buffer) were 
prepared in 1:500 dilutions and added to a 96 well plate, incubated at RT for an hour. Then the 
plate was washed, 100 µl of diluted HRP conjugated secondary antibody (1:35000 in conjugate 
buffer) was added to each well and incubated for an hour at RT. Plate was washed again. TMB 
substrate was added, incubated for 15 minutes and the reaction was stopped using stop solution 
(2N H2SO4). Finally the absorbance was measured using Fusion
®
 Packard plate reader at 450 nm. 
Unknown urinary albumin concentrations were determined from a standard curve plotted using 
assay standards in the range 7.8-500 ng/ml. 
Urinary creatinine assay  
Urinary creatinine assays were performed using a kit purchased from Quidel (San Diego, CA, 
USA). The creatinine excretion rate in a normal individual is relatively constant. Thus, urinary 
creatinine levels are useful in detecting renal disease and estimating the extent of impairment of 
23 
 
renal function. The assay is based on modified Jaffe reaction where alkaline picrate forms a 
colored solution in presence of creatinine. Standards and urinary samples were prepared in 1:40 
dilutions with distilled water and 50 µl were added to a 96 well plate. 150 µl of the working 
color solution was added to each well and incubated for 30 minutes at RT. The plate was read 
using Fusion
®
 Packard plate reader at 490 nm. Unknown urinary creatinine concentrations were 
determined from a standard curve plotted using assay standards.  
ACE2 activity 
Urinary and renal ACE2 activities were measured by fluorometric test assay. The potentiality of 
ACE2 protein to cleave the fluorogenic substrate, 7-Mca-APK-(Dnp) was used to assess the 
activity of ACE2. Cleavage of this substrate at the C-terminal Lys residue by ACE2 removes the 
2, 4-dinitrophenyl moiety that quenches the fluorescence of the 7-methoxycoumarin moiety, thus 
resulting in increased fluorescence. This emitted fluorescence was measured at excitation (λex): 
328 nm and emission (λem): 393 nm using a Fusion
®
 Packard instrument. ACE2 activity was 
measured in presence of 10 mM lisinopril, an ACE inhibitor, to prevent any interference from 
ACE.  
Western blot 
Kidneys were taken out from -80°C and homogenized on ice in lysis buffer containing PMSF 
(Complete lysis M, Roche diagnostics, Mannheim, Germany). Tissue homogenates were 
centrifuged at 10,000 x g for 10 minutes at 4° C to remove cellular debris. Total protein content 
was determined in supernatant using BSA as a standard and BioRad reagent (BioRad, Hercules, 
CA, USA). 50 µg total protein samples were loaded and allowed to run on 10% SDS-PAGE gel 
for 1 hour. After electrophoresis, proteins were electrotransferred to an activated PVDF 
membrane (Millipore, MA, USA) with the help of a Mini Trans-Blot Electrophoretic Transfer 
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cell (BioRad, Hercules, CA, USA) at 72 V for 2 hours. Membranes were then blocked and 
probed with a polyclonal antibody directed against ACE2 (1:1000, R&D Systems, MN, USA), 
ADAM17 (1:500, Enzo Life Sciences, MI, USA) and Timp3 (1:200, Santa Cruz Biotechnology, 
CA, USA) respectively followed by incubation with respective secondary HRP conjugated 
antibody. Protein signals were detected by enhanced chemiluminescence reagent and analyzed 
using a ChemiDoc imaging system (BioRad, Hercules, CA, USA). The relative amounts of 
proteins of interest in kidney and urine were determined by normalizing to β-actin and creatinine 
respectively. 
Kidney histology 
One animal from each group was perfused at the end of the 10 weeks study. Kidneys were 
excised in formalin, after washing with PBS. Kidney sections (4 µm thick) were embedded in 
paraffin and stained with periodic acid Schiff base for histopathological observations at AML 
laboratories (Baltimore, MD, USA). These sections were then analyzed for glomerular 
hypertrophy and mesangial matrix expansion. 15 to 20 glomeruli from each group were 
observed. To investigate collagen deposits, kidney sections (4 µm thick) were stained with Picro-
sirius red using Weigert’s iron hematoxylin staining kit (ENG Scientific Inc, Clifton, NJ, USA). 
Sections were dewaxed with xylene and were sequentially treated with graded alcohols in order 
to rehydrate them. Slides were then subjected to Weigert’s iron hematoxylin solution for 8 
minutes followed by tap water rinsing for 10 minutes. Then the slides were stained with Picro-
sirius red solution (5 g Direct Red 80 in 500 mL of saturated picric acid solution, Sigma-
Aldrich). Coverslips were placed and viewed with a microscope. MetaMorph software 
(Molecular Devices, CA, USA) was used for quantitation. 
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Immunohistochemistry 
Formalin fixed, paraffin-embedded kidney sections (4 µm thick) were air-dried and dewaxed 
with xylene and were sequentially treated with graded alcohols in order to rehydrate them. Then 
the slides were placed in a container holding 10mM sodium citrate buffer (pH 8.5), boiled for 30 
minutes and incubated with methanol for about 20 minutes at -20°C for retrieving the antigen. 
Then the sections were blocked with 3% normal horse serum at 4°C to avoid nonspecific 
antibody binding. Sections were washed thrice and incubated either with primary polyclonal goat 
anti-ACE2 (1:150, R&D, MN, USA) or Timp3 (1:200, Santa Cruz, USA) or rabbit anti-
ADAM17 (1:100, Enzo, USA) overnight at 4°C. Washings were repeated and the sections were 
incubated with biotinylated donkey anti-goat or anti-rabbit IgG secondary antibody conjugated 
with Cyanine 3 fluorescent dye. A drop of mounting medium was added; coverslips were placed 
and viewed with Olympus FV300 confocal microscope. MetaMorph software (Molecular 
Devices, CA, USA) was used for quantitation. 
Plasma hormone and lipids measurement  
Plasma samples collected at the end of the study were analyzed for insulin, glucose, adiponectin, 
leptin, glucagon, total cholesterol and triglyceride levels at the Mouse Metabolic Phenotyping 
Centre (Cincinnati, OH, USA). Plasma triglycerides were measured using commercially 
available assay kit (Randox Laboratories, UK). Plasma adiponectin concentration was measured 
with a mouse adiponectin ELISA kit (Millipore, St. Charles, MI, USA). Plasma levels of insulin 
and glucagon were measured using the Milliplex® MAP mouse metabolic hormone magnetic 
bead panel. Absorbance was measured using Luminex 200 (Millipore, Austin, TX). Plasma 
levels were calculated using standards provided with the Luminex kit. 
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Statistical analysis 
The differences among groups were compared by Student’s unpaired two-tailed t-test. For more 
than two groups one-way ANOVA was used. All the valves are expressed as means ± SEM. For 
multiple comparisons between two or more groups, two-way ANOVAs were carried out 
followed by Bonferroni’s multiple comparison tests. Level of significance was set at p<0.05. All 
the data was analyzed using Graph pad prism 5.01 and statistica software (v.10). 
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Table 1: Short-term effects of physical exercise training and/or metformin treatment on age dependent metabolic parameters 
Mice strain  Normal db/db  db/db+M db/db+E db/db+E+M Normal db/db  db/db+M db/db+E db/db+E+M 
Age (weeks) 6 6 6 6 6 9 9 9 9 9 
Duration of Treatment 
(weeks) 0 0 0 0 0 2 2 2 2 2 
Body weight (g) 20.5±0.4 29.7±0.8* 31.4 ± 1.3* 29.3±1.5* 30.5±0.7* 23.5±0.7 36.7±1.9* 40.0±1.4* 35.6±1.5* 36.4±1.9* 
Food intake
† 
(g/day) 4.3±0.2 6.6±0.3* ND ND ND 4.5±0.2 7.5±0.3* 7.3±0.5* 5.8±0.5*
#
 6.1±0.9*
$
 
Water intake (ml/day) 5.5±0.2 9.7±1.5* ND ND ND 5.2±0.2 18.5±3.4* 18.7±1.8* 9.8±1.3*
#
 11.1±1.1*
$
 
Urine volume (ml/day) 1.0±0.0 2.6±0.2* 2.7±0.1* 2.4±0.2* 2.4±0.4* 1.2±0.2 11.6±1.1* 11.6±0.7* 2.7±0.5*
#
 2.5±0.3*
$
 
Absolute body fat (g) 3.4±0.2 13.5±0.5* ND ND ND 4.2±0.7 20.9±0.8* 22.4±0.9* 20.0±0.9* 19.7±1.3* 
Absolute lean mass (g) 14.3±1.2 13.5±0.5 ND ND ND 16.9±1.7 14.5±0.6* 15.2±0.5 14.7±1.1* 15.6±1.7 
Total body water (%) 58.9±3.7 41.7±3.5* ND ND ND 55.1±4.1 32.4±2.8* 32.1±1.8* 33.7±2.4* 34.6±2.1* 
 
Values represent mean ± SEM. *p<0.05 vs age-matched normal mice and 
#, $
p<0.05 vs age-matched control db/db mice were 
considered statistically significant. ND means not determined. 
† 
The amount of food spilled was minimal and was not accounted for 
the data presented in the table. 
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Table 2: Long-term effects of physical exercise training and/or metformin treatment on age dependent metabolic parameters 
Mice strain  Normal db/db  db/db+M db/db+E db/db+E+M Normal db/db  db/db+M db/db+E db/db+E+M 
Age (weeks) 6 6 6 6 6 17 17 17 17 17 
Duration of Treatment 
(weeks) 0 0 0 0 0 10 10 10 10 10 
Body weight (g) 20.5±0.4 29.7±0.8* 31.4 ± 1.3* 29.3±1.5* 30.5±0.7* 28.4±0.8 39.5±2.0* 42.8±1.7* 41.7±2.0* 45.0±1.2* 
Food intake
† 
(g/day) 4.3±0.2 6.6±0.3* ND ND ND 4.5±0.3 8.1±0.4* 7.7±0.2* 5.9±0.3
#
 6.2±0.2*
$
 
Water intake (ml/day) 5.5±0.2 9.7±1.5* ND ND ND 6.4±0.3 28.8±3.6* 26.4±1.6* 16.0±3.6
#
 14.0±0.6
$
 
Urine volume (ml/day) 1.0±0.0 2.6±0.2* 2.7±0.1* 2.4±0.2* 2.4±0.4* 1.2±0.2 17.3±6.1* 16.1±5.7* 4.2±1.5
#
 3.3±1.2
$
 
Absolute body fat (g) 3.4±0.2 13.5±0.5* ND ND ND 5.5±0.6 22.4±1.3* 24.4±1.3* 20.1±1.6* 25.8±1.0* 
Absolute lean mass (g) 14.3±1.2 13.5±0.5 ND ND ND 18.9±2.6 14.9±1.8* 14.5±0.9* 15.1±1.3* 15.8±1.7* 
Total body water (%) 58.9±3.7 41.7±3.5* ND ND ND 57.7±4.6 33.6±3.4* 28.7±1.8* 29.6±2.1* 29.0±0.6* 
 
Values represent mean ± SEM. *p<0.05 vs age-matched normal mice and 
#, $
p<0.05 vs age-matched control db/db mice were 
considered statistically significant. ND means not determined. †
 
The amount of food spilled was minimal and was not accounted for 
the data presented in the table. 
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Table 3: Effects of physical exercise training and/or metformin treatment on plasma hormone and lipid parameters 
 
Mice strain  Normal db/db  db/db+M db/db+E db/db+E+M 
Age (weeks) 17 17 17 17 17 
Duration of Treatment (weeks) 10 10 10 10 10 
Plasma insulin (ng/mL) 1.4±0.3 5.0±1.2* 4.5±0.7* 16.8±2.7*
#
 15.8±3.1*
$
 
Plasma adiponectin (μg/mL) 13.5±0.8 6.6±0.6* 6.1±0.4* 8.1±1.1 8.2±1.1 
Plasma leptin (ng/mL) 4.4±0.5 11.9±1.4* 14.5±2.2* 23.2±2.3*
#
 17.5±0.9* 
Plasma glucagon (pg/mL) 14.8±3.5 101.5±6.8* 97.9±12.2* 64.2±3.6* 49.9±4.4
$
 
Plasma triglyceride (mg/dL) 115.1±11.2 271.6±34.4* 386.8±38.8*@ 137.2±25.3
#
 95.4±7.8
$
 
Plasma cholesterol (mg/dL) 115.3±6.8 113.9±8.7 113.4±4.8 112.8±8.6 107.1±5.8 
 
 
Values represent mean±SEM. *p<0.05 vs age-matched normal mice and 
@, #, $
p<0.05 vs age-matched control db/db mice were 
considered statistically significant. ND means not determined.
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Figure 1: Blood glucose levels of normal mice, db/db mice, db/db treated with metformin, db/db 
treated with exercise and db/db treated with exercise plus metformin during the period of study. 
Repeated measures two-way ANOVA using a Bonferroni’s posthoc test showed that exercise 
training alone and in combination with metformin attenuated blood glucose levels of treated 
db/db mice consistently throughout the study, p<0.001 vs untreated db/db mice. Metformin 
reduced the blood glucose levels significantly during the first 2 weeks of treatment and had no 
effect later, p<0.05 vs untreated db/db mice. Data are represented as mean ± SEM of group size 
(n=10). 
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Figure 2: Body weights of normal, db/db, db/db + metformin, db/db + exercise and db/db + 
exercise + metformin groups during the 10 weeks period of study. Repeated measures two-way 
ANOVA using a Bonferroni’s posthoc test showed that there was no significant difference in 
body weights between treated and untreated db/db mice. Data are represented as mean ± SEM of 
group size (n=10). 
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Figure 3: Food intake of normal, db/db, db/db + metformin, db/db + exercise and db/db + 
exercise + metformin groups during the 10 weeks period of study. Repeated measures two-way 
ANOVA using a Bonferroni’s posthoc test showed that physical exercise training alone and in 
combination with metformin caused a significant decrease in food intake of treated db/db mice 
throughout the study whereas, treatment with metformin had no effect, p<0.05 vs untreated db/db 
mice. Data are represented as mean ± SEM of group size (n=10). 
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Figure 4: Water intake of normal and db/db controls and db/db mice treated with metformin, 
exercise and exercise plus metformin during the 10 weeks period of study. Repeated measures 
two-way ANOVA using a Bonferroni’s posthoc test showed that physical exercise training alone 
and in combination with metformin caused a significant decrease in water intake of treated db/db 
mice throughout the study whereas treatment with metformin had no effect, p<0.05 vs untreated 
db/db mice. Data are represented as mean ± SEM of group size (n=10). 
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Figure 5: 24-hour urine output measurement from normal and db/db controls and db/db mice 
treated with metformin, exercise and exercise plus metformin during the 10 weeks period of 
study. Repeated measures two-way ANOVA using a Bonferroni’s posthoc test showed that 
physical exercise training alone and in combination with metformin caused a significant decrease 
in the urine output of treated db/db mice throughout the study whereas, treatment with metformin 
had no effect, p<0.05 vs untreated db/db mice. Data are represented as mean ± SEM of group 
size (n=10). 
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Figure 6: Percent body fat of normal and db/db controls and db/db mice treated with metformin, 
exercise and exercise plus metformin during the 10 weeks period of study. Repeated measures 
two-way ANOVA using a Bonferroni’s posthoc test showed that none of the treatments had 
effect on percent fat mass of db/db + metformin, db/db + exercise, db/db + exercise + metformin 
groups. Data are represented as mean ± SEM of group size (n=10). 
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Figure 7: Percent lean mass of normal and db/db controls and db/db mice treated with 
metformin, exercise and exercise plus metformin during the 10 weeks period of study. Repeated 
measures two-way ANOVA using a Bonferroni’s posthoc test showed that none of the 
treatments had effect on percent lean mass of db/db + metformin, db/db + exercise, db/db + 
exercise + metformin groups. Data are represented as mean ± SEM of group size (n=10). 
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Figure 8: Percent body water of normal and db/db controls and db/db mice treated with 
metformin, exercise and exercise plus metformin during the 10 weeks period of study. Repeated 
measures two-way ANOVA using a Bonferroni’s posthoc test showed that none of the 
treatments had effect on percent body water of db/db + metformin, db/db + exercise, db/db + 
exercise + metformin groups. Data are represented as mean ± SEM of group size (n=10). 
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Figure 9: Blood glucose levels in 6 weeks old db/db mice and their age-matched normal mice. 
One-way ANOVA showed a significant increase in the blood glucose levels of db/db mice 
compared to normal mice. *p<0.01 vs age-matched non-diabetic controls. Each bar represents 
mean ± SEM of group size (n=10). 
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Figure 10: Urinary albumin excretion in 6 weeks old db/db mice and their age-matched normal 
mice. One-way ANOVA showed a significant increase in albuminuria of db/db mice compared 
to normal mice. *p<0.001 vs age-matched non-diabetic controls. Each bar represents mean ± 
SEM of group size (n=10). 
 
 
 
 
 
 
 
 
 
Figure 11: Urinary total protein excretion in 6 weeks old db/db mice and their age-matched 
normal mice. One-way ANOVA showed no difference in the total protein excretion of db/db 
mice compared to normal mice. Each bar represents mean ± SEM of group size (n=10). 
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Figure 12: Urinary ACE2 activity in 6 weeks old db/db mice and their age-matched normal 
mice. One-way ANOVA showed a significant increase in the urinary ACE2 activity of db/db 
mice compared to normal mice. *p<0.01 vs age-matched non-diabetic controls. Each bar 
represents mean ± SEM of group size (n=10). 
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Figure 13: Urinary ACE2 expression in 6 weeks old db/db mice and their age-matched normal 
mice. Student’s unpaired two tailed t-test showed a significant increase in the urinary ACE2 
excretion of db/db mice compared to non-diabetic controls. *p<0.05 vs age-matched normal 
mice. Each bar represents mean ± SEM of group size (n=10). 
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Figure 14: Correlation between blood glucose levels and urinary ACE2 excretion in 6 weeks old 
db/db mice and their age-matched normal mice. Pearson correlation factor analysis showed a 
significant positive correlation between blood glucose levels and urinary ACE2 excretion. 
r=0.60, *p<0.05 vs age-matched normal mice. Each bar represents mean ± SEM of group size 
(n=10). 
 
 
 
 
 
 
 
 
Figure 15: Correlation between urinary albumin and ACE2 excretion in 6 weeks old db/db mice 
and their age-matched normal mice. Pearson correlation factor analysis showed a significant 
positive correlation between urinary albumin and ACE2 excretion. r=0.65, *p<0.05 vs age-
matched normal mice. Each bar represents mean ± SEM of group size (n=10). 
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Figure 16: At the age of 9 weeks, db/db mice had high levels of blood glucose compared to their 
age-matched normal mice. One-way ANOVA showed that, 2 weeks after the commencement of 
treatment there is a significant decrease in the blood glucose levels of db/db + metformin, db/db 
+ exercise and db/db + exercise + metformin mice compared to untreated db/db mice. 
*p<0.0001 vs age-matched normal mice, @p<0.001, 
#
p<0.0001, 
$
p<0.0001 vs control db/db 
mice. Each bar represents mean ± SEM of group size (n=10). 
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Figure 17: At the age of 9 weeks, urinary albumin excretion of db/db mice is significantly 
higher compared to normal mice. One-way ANOVA showed that after the commencement of 2 
weeks treatment, urinary albumin excretion of db/db + metformin, db/db + exercise and db/db + 
exercise + metformin groups are significantly less than control db/db group. *p<0.0001 vs age-
matched normal mice, @p<0.001, 
#
p<0.0001, 
$
p<0.0001 vs control db/db mice. Each bar 
represents mean ± SEM of group size (n=10). 
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Figure 18: At the age of 9 weeks, total protein excretion of db/db mice is significantly higher 
compared to normal mice. One-way ANOVA showed that after the commencement of 2 weeks 
treatment, exercise training alone and in combination with metformin lowered urinary total 
protein excretion in treated db/db diabetic mice compared to untreated db/db mice. Treatment 
with metformin had no effect on urinary total protein excretion. *p<0.0001 vs age-matched 
normal mice, 
#
p<0.001, 
$
p<0.001 vs control db/db mice. Each bar represents mean ± SEM of 
group size (n=10). 
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Figure 19: At the age of 9 weeks, db/db mice demonstrated higher levels of urinary ACE2 
excretion compared to normal mice. One-way ANOVA showed that 2 weeks after treatment 
commenced there is a significant decrease in urinary ACE2 excretion in db/db + metformin, 
db/db + exercise and db/db + metformin + exercise mice compared to untreated db/db mice. 
*p<0.0001 vs age-matched normal mice, @p<0.0001, 
#
p<0.0001, 
$
p<0.0001 vs control db/db 
mice. Each bar represents mean ± SEM of group size (n=10). 
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Figure 20: Urinary ACE2 expression in 9 weeks old db/db mice. One-way ANOVA showed 
that, 2 weeks after the commencement of treatment there is a significant decrease in urinary 
ACE2 expression of db/db + metformin (M), db/db + exercise (E) and db/db + exercise + 
metformin (E+M) mice compared to control db/db mice (C). @p<0.001, 
#
p<0.001, 
$
p<0.0001 vs 
control db/db mice. Each bar represents mean ± SEM of group size (n=10). 
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Figure 21: Correlation between blood glucose levels and urinary ACE2 excretion in 9 weeks old 
normal, untreated and treated db/db mice. Pearson correlation factor analysis showed that there is 
a significant positive correlation between blood glucose levels and urinary ACE2 excretion. r = 
0.73, *p<0.001. Each bar represents mean ± SEM of group size (n=10). 
 
 
 
 
 
 
 
 
 
Figure 22: Correlation between urinary albumin and ACE2 excretion in 9 weeks old normal, 
untreated and treated db/db mice. Pearson correlation factor analysis showed that there is a 
significant positive association between urinary albumin and ACE2 excretion. r = 0.65, 
*p<0.001. Each bar represents mean ± SEM of group size (n=10). 
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Figure 23: At the age of 17 weeks, db/db mice had significantly higher levels of blood glucose 
compared to normal mice. One-way ANOVA showed that after the commencement of 10 weeks 
treatment, physical exercise training alone and in combination with metformin significantly 
decreased blood glucose levels in db/db mice compared to untreated db/db mice. However, 10 
week treatment with metformin had no effect on blood glucose of treated db/db mice compared 
to control diabetic mice. *p<0.0001 vs age-matched normal mice, 
#
p<0.0001, 
$
p<0.0001 vs 
control db/db mice. Each bar represents mean ± SEM of group size (n=10). 
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Figure 24: Intra-peritoneal glucose tolerance test was performed in 17 weeks old normal mice, 
control db/db mice and db/db mice subjected to exercise training and/or metformin for 10 weeks. 
One-way ANOVA of area under curve showed that exercise training with or without metformin 
significantly improved glucose tolerance in db/db mice compared to untreated db/db mice. 
*p<0.001 vs age-matched normal mice, 
#
p<0.0001, 
$
p<0.0001 vs control db/db mice. Each bar 
represents mean ± SEM of group size (n=6). 
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Figure 25: At 17 weeks of age, urinary albumin excretion of db/db mice is significantly higher 
compared to normal mice. One-way ANOVA showed those 10 weeks after the commencement 
of treatment, physical exercise alone and in combination with metformin lowered albumin 
excretion significantly in treated db/db diabetic mice compared to untreated db/db mice. Chronic 
treatment with metformin for 10 weeks had no effect on albuminuria. *p<0.0001 vs age-matched 
normal mice, 
#
p<0.0001, 
$
p<0.0001 vs control db/db mice. Each bar represents mean ± SEM of 
group size (n=10). 
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Figure 26: At 17 weeks of age, total protein excretion of db/db mice is significantly higher 
compared to normal mice. One-way ANOVA showed those 10 weeks after the commencement 
of treatment, physical exercise alone and in combination with metformin significantly lowered 
urinary total protein excretion significantly in treated db/db diabetic mice compared to untreated 
db/db mice. Chronic treatment with metformin for 10 weeks had no effect on urinary total 
protein excretion. *p<0.0001 vs age-matched normal mice, 
#
p<0.0001, 
$
p<0.0001 vs control 
db/db mice. Each bar represents mean ± SEM of group size (n=10). 
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Figure 27: At the age of 17 weeks, db/db mice excreted significantly higher levels of urinary 
ACE2 compared to normal mice. One-way ANOVA showed that 10 week training with physical 
exercise training alone and in combination with metformin attenuated urinary ACE2 excretion in 
db/db mice compared to untreated db/db mice. In contrast, 10 week treatment with metformin 
had no effect on urinary ACE2 excretion of treated db/db mice compared to control diabetic 
mice. *p<0.0001 vs age-matched normal mice, 
#
p<0.0001, 
$
p<0.0001 vs control db/db mice. 
Each bar represents mean ± SEM of group size (n=10). 
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Figure 28: Urinary ACE2 expression in 17 weeks old db/db mice. One-way ANOVA showed 
that after the commencement of 10 weeks treatment, exercise training (E) alone and in 
combination with metformin (E+M) lowered urinary levels of ACE2 excretion in treated db/db 
diabetic mice compared to untreated db/db mice (C). Treatment with metformin for 10 weeks 
had no effect on urinary ACE2 expression of treated db/db mice (M). 
#
p<0.01, 
$
p<0.01 vs 
control db/db mice. Each bar represents mean ± SEM of group size (n=10). 
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Figure 29: Correlation between blood glucose levels and urinary ACE2 excretion in 17 weeks 
old normal, untreated and treated db/db mice. Pearson correlation factor analysis showed a 
significant positive correlation between blood glucose levels and urinary ACE2 excretion. r = 
0.75, *p<0.0001. Each bar represents mean ± SEM of group size (n=10). 
 
 
 
 
 
 
 
Figure 30: Correlation between urinary albumin and ACE2 excretion in 17 weeks old normal, 
untreated and treated db/db mice. Pearson correlation factor analysis showed a significant 
positive association between urinary albumin and ACE2 excretion. r = 0.84, *p<0.0001. Each 
bar represents mean ± SEM of group size (n=10). 
 
 
 
 
0 1 2 3
0
30
60
90
120
150 r = 0.84
p < 0.0001
Urinary albumin excretion (mg/day)
U
ri
n
ar
y
 A
C
E
2
 a
c
ti
v
it
y
(n
m
o
ls
/h
r/
m
g
 C
r)
56 
 
         
                                   
 
Figure 31: Renal ADAM17 protein expression in 17 weeks old normal, untreated and treated 
db/db mice. One-way ANOVA showed increased renal ADAM17 protein expression in db/db 
diabetic mice compared to their age-matched non-diabetic mice. 10 weeks exercise training 
alone and in combination with metformin attenuated ADAM17 protein in kidneys of treated 
db/db mice compared to untreated db/db mice. In contrast, 10 week treatment with metformin 
had no effect on renal ADAM17 protein levels of treated db/db mice compared to untreated 
diabetic mice. 
#
p<0.01, 
$
p<0.01 vs control db/db mice. Each bar represents mean ± SEM of 
group size (n=10). 
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Figure 32: Renal Timp3 protein expression in 17 weeks old normal, untreated and treated db/db 
mice. One-way ANOVA showed that there was no difference in renal Timp3 protein levels 
among normal, db/db, db/db + metformin, db/db + exercise and db/db + exercise + metformin 
groups. Each bar represents mean ± SEM of group size (n=10). 
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Figure 33: Renal ACE2 protein expression in 17 weeks old normal, untreated and treated db/db 
mice. One-way ANOVA showed increased renal ACE2 protein expression in db/db diabetic 
mice compared to their age-matched non-diabetic mice. After the commencement of 10 weeks 
treatment, there was no difference in renal ACE2 expression in db/db, db/db + metformin, db/db 
+ exercise and db/db + exercise + metformin groups. *p<0.001 vs age-matched non-diabetic 
mice. Each bar represents mean ± SEM of group size (n=10). 
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Figure 34: Renal ACE2 activity in 17 weeks old normal, untreated and treated db/db mice. One-
way ANOVA showed a significant increase in the renal ACE2 activity of db/db mice compared 
to their age-matched non-diabetic mice. After the commencement of 10 weeks treatment, there 
was no difference in the renal ACE2 activity of db/db, db/db + metformin, db/db + exercise and 
db/db + exercise + metformin groups. *p<0.0001 vs age-matched normal mice. Each bar 
represents mean ± SEM of group size (n=10). 
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Figure 35: Correlation between plasma glucagon and urinary ACE2 excretion in 17 weeks old 
normal, untreated and treated db/db mice. Pearson correlation factor analysis showed a 
significant positive correlation between plasma glucagon levels and urinary ACE2 excretion. r = 
0.66, *p<0.001. Each bar represents mean ± SEM of group size (n=10). 
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Figure 36: Correlation between plasma triglycerides and urinary ACE2 excretion in 17 weeks 
old normal, untreated and treated db/db mice. Pearson correlation factor analysis showed a 
significant positive correlation between plasma triglyceride levels and urinary ACE2 excretion. 
r=0.75, *p<0.001. Each bar represents mean ± SEM of group size (n=10). 
 
 
 
 
 
 
 
Figure 37: Correlation between plasma insulin and urinary ACE2 excretion in 17 weeks old 
normal, untreated and treated db/db mice. Pearson correlation factor analysis showed a 
significant negative correlation between plasma insulin levels and urinary ACE2 excretion. r = -
0.54, *p<0.05. Each bar represents mean ± SEM of group size (n=10). 
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Figure 38: Urinary albumin excretion in 17 weeks old normal untreated, normal + metformin 
and normal + exercise mice. One-way ANOVA showed those 10 weeks after the commencement 
of treatment, there is a significant increase in urinary albumin excretion of normal + exercise 
mice compared to their age-matched untreated normal mice. However, treatment with metformin 
for 10 weeks had no effect on urinary albumin levels. *p<0.0001 vs age-matched normal mice. 
Each bar represents mean ± SEM of group size (n=10). 
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Figure 39: Urinary ACE2 excretion in 17 weeks old normal untreated, normal + metformin and 
normal + exercise groups. One-way ANOVA showed no difference in urinary ACE2 excretion of 
untreated normal mice, normal mice treated with metformin and normal mice trained with 
exercise. Each bar represents mean ± SEM of group size (n=10). 
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Figure 40: Representative PAS stained photomicrographs from A) Normal, B) db/db, C) db/db + 
metformin, D) db/db + exercise, E) db/db + exercise + metformin mice are shown along with 
graphs displaying the magnitude of mesangial expansion. Original magnification: x200. There 
was a significant increase in the mesangial matrix and glomerular surface areas of db/db diabetic 
mice compared to their age-matched non-diabetic mice. 10 weeks exercise training alone and in 
combination with metformin attenuated mesangial matrix expansion and glomerular surface area 
of treated db/db mice compared to untreated db/db mice. In contrast, 10 week treatment with 
metformin had no effect on the relative mesangial matrix and glomerular surface areas of db/db 
mice. *p<0.0001 vs age-matched normal mice, 
#
p<0.0001, 
$
p<0.0001 vs control db/db mice. 
Each bar represents mean ± SEM of group size (n=no of glomeruli=20). 
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Figure 41: Representative Picro-sirius stained photomicrographs from A) Normal, B) db/db, C) 
db/db + metformin, D) db/db + exercise, E) db/db + exercise + metformin mice are shown along 
with graphs displaying the magnitude of collagen deposits. Original magnification: x200. 
Collagen deposition was significantly increased in db/db diabetic mice compared to their age-
matched non-diabetic mice. 10 week training with physical exercise alone and in combination 
with metformin attenuated collagen deposition of treated db/db mice compared to untreated 
db/db mice. In contrast, 10 week treatment with metformin had no effect on collagen deposits of 
db/db mice. *p<0.0001 vs age-matched normal mice, 
#
p<0.0001, 
$
p<0.0001 vs control db/db 
mice. Each bar represents mean ± SEM of group size. 
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Figure 42: Representative photomicrographs from A) Normal, B) db/db, C) db/db + metformin, 
D) db/db + exercise, E) db/db + exercise + metformin mice are shown along with graphs 
displaying the magnitude of intensity of staining for ADAM17 protein. Original magnification: 
x200. ADAM17 immunostaining was significantly increased in 17 week db/db mice compared to 
their age-matched non-diabetic mice. After the commencement of 10 weeks treatment, staining 
was significantly decreased in db/db + exercise and db/db + exercise + metformin groups 
compared to untreated db/db and db/db + metformin mice. Metformin had no effect on renal 
ADAM17 protein expression in db/db mice compared to untreated db/db group. *p<0.0001 vs 
age-matched normal mice, 
#
p<0.0001, 
$
p<0.0001 vs control db/db mice. Each bar represents 
mean ± SEM of group size. 
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Figure 43: Representative photomicrographs from A) Normal, B) db/db, C) db/db + metformin, 
D) db/db + exercise, E) db/db + exercise + metformin mice are shown along with graphs 
displaying the magnitude of intensity of staining for ACE2 protein. Original magnification: 
x200. Expression patterns of ACE2 protein was significantly decreased in glomeruli and 
increased in tubules of db/db mice compared to normal mice. Glomerular ACE2 protein was 
significantly increased in 17 wks old db/db mice subjected to exercise training with or without 
metformin. However, treatment with metformin alone had no effect on glomerular ACE2 protein 
expression compared to control db/db mice. Alternatively, no difference was seen in the tubular 
ACE2 protein expression of control db/db mice and db/db mice subjected to exercise training 
with or without metformin. *p<0.0001 vs age-matched normal mice, 
#
p<0.0001, 
$
p<0.0001 vs 
control db/db mice. Each bar represents mean ± SEM of group size. 
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Figure 44: Double-immunofluorescence staining of ACE2 (green; left) and ADAM17 (red; 
middle) in cortical tubules of db/db mice. Original magnification: x200. Merge of both images 
(yellow; right) demonstrates co-localization of ACE2 and ADAM17 in the tubular cortex of 
diabetic db/db mice. 
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4. RESULTS 
4.1. General physiologic, metabolic and body composition parameters 
To examine the age-dependent changes in db/db mice, the following parameters were monitored 
weekly. 
a) Blood glucose: At 6 weeks of age db/db mice exhibited significantly higher levels of blood 
glucose compared to normal mice. Indeed, there was a progressive increase in blood glucose 
levels of db/db mice over time (Figure 1, *p<0.01, unpaired-t test). Moreover, db/db mice had 
impaired glucose tolerance in an intra-peritoneal glucose tolerance test (Figure 24, *p<0.001). 
However, these differences were not seen in normal mice during the study period.  
b) Body weight: At 6 weeks, db/db mice weighed significantly more than the normal mice 
(Table 1, *p<0.001). In fact, there was a consistent upregulation in the body weight of db/db 
mice over time and with age when compared to normal mice (Table 1&2, *p<0.01, unpaired-t 
test).  
c) Food intake: At 6 weeks, db/db mice demonstrated a significant increase in the food intake 
compared to normal mice (Table 1, *p<0.001). Similarly, food intake of db/db mice was 
significantly more at 9 weeks and 17 weeks (Table 1&2, *p<0.01, unpaired-t test). However, no 
difference was observed in the food intake of normal mice over time. 
d) Water intake: At 6 weeks, db/db mice demonstrated significantly higher levels of water 
intake compared to normal mice (Table 1, *p<0.001). Similarly, water intake of db/db mice 
increased significantly at 9 weeks and 17 weeks (Table 1&2, *p<0.001, unpaired-t test). 
However, no difference was observed in the water intake of normal mice over time. 
e) Urine output per day: At 6 weeks, db/db mice excreted significantly higher volumes of urine 
compared to age-matched normal mice (Table 1, *p<0.001, unpaired-t test). In fact, there was a 
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consistent increase in 24-hour urine volumes of db/db mice over time (Table 1&2, *p<0.001). 
However, no difference was observed in the urine output of normal mice over time. 
f) Absolute body fat: At 6 weeks, absolute body fat of db/db mice was significantly high 
compared to normal mice (Table 1, *p<0.001, unpaired-t test). Moreover, there was a consistent 
increase in the absolute body fat of db/db mice over time (Table 1&2, *p<0.001). 
g) Absolute lean mass: db/db mice exhibited a significantly lower content of absolute lean mass 
at 6 weeks, 9 weeks and 17 weeks compared to their age-matched normal mice (Table 1&2, 
*p<0.001, unpaired t-test). 
h) Total body water: db/db mice exhibited a significantly lower content of total body water 
compared to normal mice in the juvenile stages (6 weeks) (Table 1, *p<0.001). Decrease in the 
total body water content was also seen in 9 and 17 week old db/db mice (Table 1&2, *p<0.001). 
 
4.2.  Plasma hormone and lipid parameters 
To assess the effect of hyperglycemia on hormonal changes in type 2 diabetes, following 
parameters were measured.  
a) Plasma insulin: One of the important characteristics of db/db mice is hyperinsulinemia. 
Plasma insulin levels were significantly elevated in 17 week old db/db mice compared to age-
matched normal mice (Table 3, *p<0.0001). 
b) Plasma leptin: There was a significant increase in the plasma leptin levels of 17 week old 
db/db mice compared to normal mice (Table 3, *p<0.001). 
c) Plasma glucagon: Glucagon levels were significantly elevated in the plasma of 17 week old 
db/db mice compared to normal mice (Table 3, *p<0.0001). 
d) Plasma adiponectin: Levels of plasma adiponectin was significantly decreased in 17 week 
old db/db mice compared to age-matched normal mice (Table 3, *p<0.0001). 
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e) Plasma triglycerides: Plasma triglyceride levels were significantly elevated in 17 week old 
db/db mice compared to their age-matched normal mice (Table 3, *p<0.0001). 
f) Plasma cholesterol: At 17 weeks, there was no difference in the plasma cholesterol levels of 
db/db mice compared to age-matched normal mice (Table 3). 
4.3. Assessment of renal function  
To investigate the effect of hyperglycemia on diabetic nephropathy, urinary albumin and total 
protein excretions were measured in 24-hour urine samples. 
a) Urinary albumin: There was a significant increase in the urinary albumin excretion of 6 week 
old db/db mice compared to normal mice (Figure 10, *p<0.001). With the progression of age, 
urinary albumin levels were up-regulated consistently in db/db mice compared to their age-
matched normal mice. Indeed, there was an age-dependent increase in albumin excretion of 
db/db diabetic mice (Figure 17&25, *p<0.0001).  
b) Urinary total protein: We observed no differences in the total protein excretion of diabetic 
and non-diabetic mice at juvenile stages (6 weeks) (Figure 11). However, with the progression of 
age there was a significant increase in the urinary total protein excretion of db/db mice compared 
to their age-matched normal mice. In addition, there was an age-dependent increase in total 
proteinuria of db/db mice (Figure 18&26, *p<0.0001). 
4.4. Enzyme activities measurement  
To evaluate the effect of hyperglycemia on ACE2 activity, 24-hour urine samples and whole 
kidney lysates were analyzed using a fluorogenic substrate. 
a) Urinary ACE2 activity: To demonstrate the activity of ACE2 in urine, 24-hour urinary 
samples were incubated with Mca-APK (Dnp) fluorogenic substrate. In fact, there was a 
significant increase in the urinary ACE2 activity of 6 week old db/db mice compared to age-
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matched normal mice (Figure 12, *p<0.01). Similar trend was observed in the urine samples 
from 9 week and 17 week old mice (Figure 19&27, *p<0.01).  
b) Renal ACE2 activity: To investigate the protective role of ACE2 in diabetic nephropathy, 
renal ACE2 activity was measured in the whole kidney lysate using Mca-APK (Dnp) fluorogenic 
substrate. There was a significant increase in renal ACE2 activity of 17 week old db/db mice 
compared to age-matched normal mice (Figure 34, *p<0.0001). 
4.5. Protein expression of urinary ACE2, renal ADAM17, Timp3 and ACE2 
To investigate the effect of hyperglycemia on shedding of renal ACE2, whole kidney lysates 
from 17 week old db/db and normal mice were analyzed using immunoblot analyses.  
a) Urinary ACE2 protein expression: Urinary ACE2 protein expression was significantly 
increased in 6 week, 9 week and 17 week old db/db mice compared to their age-matched normal 
mice as confirmed from the western blot analyses (Figure 13,20&28, *p<0.05). 
b) Renal ADAM17 protein expression: ADAM17 protein content was significantly upregulated 
in 17 week old db/db mice compared to age-matched normal mice as confirmed from the western 
blot results (Figure 31, *p<0.001). 
c) Renal Timp3 protein expression: No difference was observed in renal Timp3 protein levels of 
17 week old diabetic and non-diabetic mice (Figure 32). 
d) Renal ACE2 protein expression: Immunoblot analyses demonstrated that ACE2 protein 
expression was significantly increased in the whole kidney lysate of 17 week old db/db mice 
compared to their age-matched normal mice (Figure 33, *p<0.001).  
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4.6. Histopathology 
To investigate the distribution patterns of ADAM17 and ACE2 in the kidney, immunostaining 
analyses were performed on the kidney sections obtained from perfused mice. In addition, to 
evaluate the renal pathologies, PAS and Picro-sirius red stained kidney sections were analyzed. 
a) Immunostaining for renal ADAM17: In concordance with immunoblot analyses, staining for 
ADAM17 was significantly high in the kidney of 17 week old db/db mice compared to age-
matched normal mice (Figure 42, *p<0.0001).  
b) Immunostaining for renal ACE2: Immunostaining result showed a significantly increased 
and decreased staining for ACE2 in the tubular and glomerular kidney of 17 week old db/db 
mice compared to age-matched normal mice respectively (Figure 43, *p<0.0001). 
c) PAS staining: PAS stained kidney sections from 17 week old db/db mice demonstrated a 
significantly increased glomerular surface area and expanded mesangial matrix compared to age-
matched normal mice (Figure 40, *p<0.0001). 
d) Picro-sirius red staining: Collagen deposition was significantly increased in the kidney of 17 
week old db/db mice compared to age-matched normal mice (Figure 41, *p<0.0001).  
4.7. Correlation of urinary ACE2 with blood glucose and albuminuria 
To investigate the potentiality of urinary ACE2 as a risk marker in diabetes, it was correlated 
with the following parameters. 
a) With blood glucose: To identify statistically significant relationship between urinary ACE2 
and blood glucose, Pearson correlations were calculated between these variables in normal and 
four different groups of diabetic db/db mice when they were 6 week old. There was a significant 
and positive correlation between urinary ACE2 and the blood glucose levels (Figure 14, r = 0.60, 
*p<0.05).   
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b) With albuminuria: To identify statistically significant relationship between urinary ACE2 and 
albumin excretion, Pearson correlations were calculated between these variables in normal and 
four different groups of diabetic db/db mice when they were 6 week old. There was a significant 
and positive correlation between urinary ACE2 and albuminuria (Figure 15, r = 0.65, *p<0.05).   
4.8. Short term intervention with exercise, metformin and combination  
To evaluate the short term effects of lowering hyperglycemia on type 2 diabetes related 
metabolic parameters, juvenile (7 week) db/db mice were subjected to exercise training and/or 
metformin treatment for 2 weeks. 
a) Effect of exercise, metformin and combination on blood glucose: Short term intervention 
with exercise and/or metformin significantly lowered blood glucose levels in db/db mice 
compared to untreated db/db mice (Figure 16, @p<0.0001, 
#
p<0.0001, 
$
p<0.0001). Blood glucose 
lowering effect was seen as early as 1 week after the initiation of treatment. However, normal 
mice subjected to exercise and/or metformin intervention did not show a difference in their blood 
glucose levels compared to control normal mice.  
b) Effect of exercise, metformin and combination on body weights: Neither exercise trained nor 
metformin treated db/db mice exhibited difference in their body weights compared to untreated 
db/db mice (Table 1). 
c) Effect of exercise, metformin and combination on food intake: Exercise training alone and in 
combination with metformin for 2 weeks attenuated food intake of db/db mice (Table 1, 
#
p<0.05, 
$
p<0.01). However, administration of metformin for 2 weeks had no effect compared to control 
db/db mice. Similarly, no difference was observed in the food intake of untreated and treated 
normal mice.  
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d) Effect of exercise, metformin and combination on water intake: Exercise training alone and 
in combination with metformin for 2 weeks attenuated water intake of db/db mice (Table 1, 
#
p<0.05, 
$
p<0.05). However, administration of metformin for 2 weeks had no effect compared to 
control db/db mice. No difference was observed in water intake of untreated and treated normal 
mice.  
e) Effect of exercise, metformin and combination on urine output: Exercise training alone and 
in combination with metformin for 2 weeks attenuated 24-hour urinary output of db/db mice 
(Table 1, 
#
p<0.001, 
$
p<0.001). However, administration of metformin to db/db mice for 2 weeks 
had no effect compared to control db/db mice. Similarly, no difference was observed in the 
urinary output of untreated and treated normal mice.  
f) Effect of exercise, metformin and combination on absolute body fat: Short term intervention 
with exercise and/or metformin for 2 weeks had no effect on the absolute body fat of db/db mice 
as well as normal mice (Table 1). 
g) Effect of exercise, metformin and combination on absolute lean mass: No differences were 
noticed in the absolute lean mass of db/db mice and normal mice that are subjected to exercise 
training and/or metformin treatment for 2 weeks (Table 1). 
h) Effect of exercise, metformin and combination on total body water: Intervention with 
exercise and/or metformin for 2 weeks had no effect on the total body water content of db/db 
mice as well as normal mice (Table 1). 
4.9. Effect of exercise, metformin and combination on renal function  
To investigate the effect of lowering hyperglycemia by exercise and/or metformin on the renal 
function, following parameters were measured.  
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a) Urinary albumin: Physical exercise for 2 weeks significantly attenuated urinary albumin 
excretion of trained db/db mice compared to control db/db mice. Indeed, short term treatment 
with metformin improved albuminuria of db/db mice (Figure 17, @p<0.001, 
#
p<0.0001, 
$
p<0.0001). 
b) Urinary total protein excretion: Physical exercise for 2 weeks significantly attenuated urinary 
total protein excretion of trained db/db mice compared to control db/db mice (Figure 18, 
#
p<0.001, 
$
p<0.001). However, administration of metformin for 2 weeks had no effect on the 
urinary total protein excretion of in db/db mice compared to untreated db/db mice (Figure 18). 
4.10. Effect of exercise, metformin and combination on urinary ACE2 activity  
a) Urinary ACE2 activity: Diabetic db/db mice subjected to exercise training and/or metformin 
treatment for 2 weeks demonstrated a significant decrease in their urinary ACE2 excretion 
compared to untreated db/db mice (Figure 19, @p<0.0001, 
#
p<0.0001, 
$
p<0.0001). 
4.11. Effect of exercise, metformin and combination on urinary ACE2 protein expression 
a) Urinary ACE2 protein expression: Urinary ACE2 protein expression was significantly 
attenuated in 9 week old db/db mice subjected to exercise training and/or metformin treatment 
for 2 weeks compared to untreated db/db mice (Figure 20, @p<0.001, 
#
p<0.001, 
$
p<0.0001). 
4.12. Correlation of urinary ACE2  
To investigate the potentiality of urinary ACE2 as a risk marker in type 2 diabetes, it was 
correlated with the following parameters from 9 week old control normal, control db/db and 
db/db mice subjected to exercise and/or metformin for 2 weeks. 
a) With blood glucose: To identify statistically significant relationship between urinary ACE2 
and blood glucose, Pearson correlations were calculated between these variables in the total 
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groups of 9 week old mice after 2 weeks intervention with exercise and/or metformin. Urinary 
ACE2 was significantly and positively correlated with the blood glucose levels (Figure 21, r = 
0.73, p<0.001).   
b) With albuminuria: To identify statistically significant relationship between urinary ACE2 and 
albumin excretion, Pearson correlations were calculated between these variables in the total 
groups of 9 week old mice after 2 weeks intervention with exercise and/or metformin. Urinary 
ACE2 was significantly and positively correlated with albuminuria (Figure 22, r = 0.65, 
p<0.001).   
4.13. Long term intervention with exercise, metformin and combination  
To evaluate the long term effect of lowering hyperglycemia on type 2 diabetes related metabolic 
and renal parameters, exercise training and/or metformin treatment was continued for 10 weeks. 
a) Effect of exercise, metformin and combination on blood glucose: Chronic intervention with 
physical exercise with or without metformin significantly lowered blood glucose levels of 
intervened db/db mice compared to control db/db mice (Figure 23, 
#
p<0.0001, 
$
p<0.0001). In 
fact, blood glucose lowering effect of exercise was consistent during the study period. In 
contrast, chronic treatment with metformin for 10 weeks had no effect on blood glucose levels of 
treated db/db mice compared to untreated db/db mice (Figure 23). However, normal mice 
subjected to exercise and/or metformin intervention did not show a difference in their blood 
glucose levels compared to untreated normal mice. In addition, physical exercise training with or 
without metformin ameliorated glucose utilization in intervened db/db mice compared to 
untreated diabetic mice (Figure 24, 
#
p<0.0001, 
$
p<0.0001). Alternatively, metformin treatment 
had no effect (Figure 24).  
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b) Effect of exercise, metformin and combination on body weights: Intervention with exercise 
and/or metformin for 10 weeks had no effect on the body weights of intervened db/db mice 
compared to untreated db/db mice. Similarly, no difference was seen in the body weights of 
intervened and control normal mice (Table 2). 
c) Effect of exercise, metformin and combination on food intake:  Exercise training with or 
without metformin for 10 weeks attenuated food intake of intervened db/db mice compared to 
untreated db/db mice (Table 2, 
#
p<0.01, 
$
p<0.01). On the otherhand, metformin treatment of 
db/db mice for 10 weeks had no effect. Similarly, no difference was seen in the food intake of 
exercise trained and metformin treated normal mice compared to control normal mice.  
d) Effect of exercise, metformin and combination on water intake: Exercise training alone and 
in combination with metformin for 10 weeks attenuated water intake of db/db mice (Table 2, 
#
p<0.01, 
$
p<0.01). However, administration of metformin for 10 weeks had no effect compared 
to untreated db/db mice. Similarly, no difference was seen water intake of exercise trained and 
metformin treated normal mice compared to control normal mice.  
e) Effect of exercise, metformin and combination on urine output: Chronic intervention with 
exercise alone and in combination with metformin attenuated 24-hour urinary output of db/db 
mice (Table 2, 
#
p<0.001, 
$
p<0.001). Treatment of db/db mice with metformin for 10 weeks had 
no effect on 24-hour urinary volumes compared to untreated db/db mice. Similarly, no difference 
was seen in the urinary output of exercise trained, metformin treated and control normal mice.  
f) Effect of exercise, metformin and combination on absolute body fat: Chronic intervention 
with exercise and/or metformin for 10 weeks had no effect on the absolute body fat of db/db 
mice as well as normal mice (Table 2). 
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g) Effect of exercise, metformin and combination on absolute lean mass: No differences were 
seen in the absolute lean mass of db/db mice and normal mice that are subjected to exercise 
training and/or metformin treatment for 10 weeks compared to their respective controls (Table 
2). 
h) Effect of exercise, metformin and combination on total body water: Intervention with 
exercise and/or metformin for 10 weeks had no effect on the total body water content of db/db 
mice as well as normal mice (Table 2). 
4.14. Effect of exercise, metformin and combination on plasma hormone parameters: 
To examine the effect of lowering hyperglycemia on type 2 diabetes related plasma hormonal 
and lipid changes, measurements of the following were carried out using plasma from untreated 
and treated db/db mice. 
a) Plasma insulin levels:  Chronic intervention with exercise training alone and in combination 
with metformin for 10 weeks, significantly increased plasma insulin levels of db/db mice 
compared to untreated db/db mice (Table 3, 
#
p<0.0001, 
$
p<0.0001). However, administration of 
metformin for 10 weeks had no effect on plasma insulin levels of treated db/db mice compared to 
untreated db/db mice (Table 3).  
b) Plasma leptin levels: Physical exercise for 10 weeks significantly increased the plasma 
leptin levels of trained db/db mice compared to control db/db mice (Table 3, 
#
p<0.05). 
Interestingly, administration of metformin prevented this effect of exercise in db/db mice. On the 
otherhand, treatment with metformin alone had no effect compared to untreated db/db mice.  
c) Plasma adiponectin levels: Chronic intervention with exercise and/or metformin had no 
effect on the plasma adiponectin levels in intervened db/db mice compared to untreated db/db 
mice (Table 3).  
80 
 
d) Plasma triglyceride levels: Physical exercise with or without metformin significantly 
reduced plasma triglyceride levels of trained db/db mice compared to control db/db mice (Table 
3, 
#
p<0.0001, 
$
p<0.0001). Metformin treatment significantly increased plasma triglyceride levels 
of treated db/db mice compared to untreated db/db mice (Table 3, @p<0.05). 
e) Plasma glucagon levels: Neither exercise training nor metformin treatment improved 
plasma glucagon levels of db/db mice individually. However, combination of exercise and 
metformin significantly reduced plasma glucagon levels of intervened db/db mice compared to 
untreated db/db mice (Table 3, 
$
p<0.0001). 
f) Plasma cholesterol levels: No differences were seen in the plasma cholesterol levels of 
exercise trained, metformin treated and untreated db/db (Table 3). 
4.15. Effect of exercise, metformin and combination on renal function  
To investigate the chronic effect of lowering hyperglycemia by exercise and/or metformin on the 
renal function, following parameters were measured.  
a) Urinary albumin: Physical exercise training with or without metformin for 10 weeks 
significantly attenuated urinary albumin excretion in intervened db/db mice compared to 
untreated db/db mice (Figure 25, 
#
p<0.0001, 
$
p<0.0001). However, there was a significant 
increase in the urinary albumin levels of normal mice subjected to exercise training compared to 
control normal mice (Figure 38, 
#
p<0.0001). On the otherhand, administration of metformin for 
10 weeks had no effect on the urinary albumin levels of treated and untreated diabetic and non-
diabetic mice (Figure 24). 
b) Urinary total protein excretion: Physical exercise training with or without metformin for 10 
weeks significantly attenuated urinary total protein excretion of intervened db/db mice compared 
81 
 
to untreated db/db mice (Figure 26, 
#
p<0.0001, 
$
p<0.0001). However, metformin treatment for 
10 weeks had no effect on the total protein excretion of treated db/db mice compared to untreated 
db/db mice (Figure 26). On the otherhand, no difference was seen in the urinary total protein 
levels of intervened and control normal mice.  
4.16. Effect of exercise, metformin and combination on enzyme activities  
a) Urinary ACE2 activity: Diabetic db/db mice subjected to exercise training with or without 
metformin for 10 weeks demonstrated a significant decrease in their urinary ACE2 activity 
compared to untreated db/db mice (Figure 27, 
#
p<0.0001, 
$
p<0.0001). In contrast, administration 
of metformin for 10 weeks had no effect on the urinary ACE2 activity of 17 week old treated 
db/db mice compared to untreated db/db mice (Figure 26). Similarly, no difference was seen in 
the urinary ACE2 excretion of exercise trained, metformin treated and control normal mice 
(Figure 39). 
b) Renal ACE2 activity: No differences were seen in the renal ACE2 activity of 17 week old 
control db/db mice and age-matched db/db mice intervened with exercise and/or metformin for 
10 weeks (Figure 34). Similarly, no difference was seen in the renal ACE2 activity of exercise 
trained, metformin treated and control normal mice. 
4.17. Effect of exercise, metformin and combination on protein expression of Urinary ACE2, 
renal ADAM17, Timp3 and ACE2 
To investigate the effect of lowering hyperglycemia on shedding of renal ACE2, 24-hour urine 
sample and whole kidney lysates from 17 week old db/db mice subjected to exercise and/or 
metformin were analyzed using immunoblot analyses.  
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a) Urinary ACE2 protein expression: Physical exercise training with or without metformin for 
10 weeks significantly attenuated urinary ACE2 protein excretion in 17 week old trained db/db 
mice compared to untreated db/db mice (Figure 28, 
#
p<0.01, 
$
p<0.01). In contrast, chronic 
treatment with metformin had no effect on urinary ACE2 protein levels of treated db/db mice 
compared to untreated db/db mice (Figure 28).  
b) Renal ADAM17 protein expression: Physical exercise training with or without metformin for 
10 weeks significantly reduced ADAM17 protein expression in the kidney of 17 week old db/db 
mice compared to their age-matched untreated db/db mice (Figure 31, 
#
p<0.01, 
$
p<0.01).  
Alternatively, treatment with metformin for 10 weeks had no effect on the renal ADAM17 
protein content of treated db/db mice compared to untreated db/db mice (Figure 31).  
c) Renal Timp3 protein expression: No difference was seen in renal Timp3 protein levels of 17 
weeks old control db/db mice and db/db mice subjected to exercise training, metformin treatment 
and exercise plus metformin for 10 weeks (Figure 32). 
d) Renal ACE2 protein expression: Immunoblot analyses demonstrated no differences in renal 
ACE2 protein expression of 17 week old db/db mice subjected to exercise and/or metformin 
compared to untreated db/db mice (Figure 33).  
4.18. Histopathology 
To investigate the effect of lowering hyperglycemia on the distribution pattern of ADAM17 and 
ACE2 proteins in the kidney, immunostaining analyses were performed on the kidney sections 
obtained from perfused mice that are subjected to exercise and/or metformin for 10 weeks. In 
addition, to evaluate the effect of lowering hyperglycemia on the renal pathologies, PAS and 
Picro-sirius red stained kidney sections were analyzed. 
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a) Immunostaining for renal ADAM17: In concordance with the western blot analyses, staining 
for ADAM17 was significantly reduced in exercise trained db/db mice compared to untreated 
db/db mice (Figure 42, 
#
p<0.0001, 
$
p<0.0001). Metformin treatment had no effect on renal 
ADAM17 protein levels in db/db mice compared to untreated db/db mice (Figure 42). 
b) Immunostaining for renal ACE2: Glomerular ACE2 protein was significantly increased in 17 
weeks old db/db mice subjected to physical exercise training with or without metformin for 10 
weeks (Figure 43, 
#
p<0.0001, 
$
p<0.0001). However, treatment with metformin alone had no 
effect on glomerular ACE2 protein expression compared to untreated db/db mice. No difference 
was seen in the tubular ACE2 protein expression of untreated db/db mice and db/db mice 
subjected to exercise and/or metformin for 10 weeks (Figure 43). 
c) PAS staining: Chronic intervention with exercise training alone and in combination with 
metformin reduced glomerular surface area significantly and attenuated mesangial expansion in 
db/db mice (Figure 40, 
#
p<0.0001, 
$
p<0.0001). This effect was not seen in metformin treated 
db/db mice compared to untreated db/db mice (Figure 40). 
d) Picro-sirius red staining: Physical exercise training alone and in combination with metformin 
for 10 weeks was associated with significantly reduced collagen deposits in db/db mice 
compared to untreated db/db mice (Figure 41, 
#
p<0.0001, 
$
p<0.0001). This effect was not seen 
in metformin treated db/db mice compared to untreated db/db mice (Figure 41). 
4.19. Correlation of urinary ACE2  
To investigate the potentiality of urinary ACE2 as a risk marker in type 2 diabetes, it was 
correlated with the results obtained from 17 week old control normal, db/db and db/db mice 
subjected to exercise and/or metformin for 10 weeks. 
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a) With blood glucose: To identify statistically significant relationship between urinary ACE2 
and blood glucose, Pearson correlations were calculated between these variables in the total 
groups of 17 week old mice after 10 weeks intervention with exercise and/or metformin. Urinary 
ACE2 was significantly and positively correlated with the blood glucose levels (Figure 29, r = 
0.75, p<0.0001).   
b) With albuminuria: To identify statistically significant relationship between urinary ACE2 and 
albumin excretion, Pearson correlations were calculated between these variables in the total 
groups of 17 week old mice after 10 weeks intervention with exercise and/or metformin. Urinary 
ACE2 was significantly and positively correlated with albuminuria (Figure 30, r = 0.84, 
p<0.0001).   
c) With plasma glucagon: To identify statistically significant relationship between urinary 
ACE2 and plasma glucagon levels, Pearson correlations were calculated between these variables 
in the total groups of 17 week old mice after 10 weeks intervention with exercise and/or 
metformin. Urinary ACE2 was significantly and positively correlated with plasma glucagon 
(Figure 35, r = 0.66, p<0.001).   
d) With plasma triglycerides: To identify statistically significant relationship between urinary 
ACE2 and plasma triglyceride levels, Pearson correlations were calculated between these 
variables in the total groups of 17 week old mice after 10 weeks intervention with exercise 
and/or metformin. Urinary ACE2 was significantly and positively correlated with plasma 
triglyceride levels (Figure 36, r = 0.75, p<0.001).   
e) With plasma insulin: To identify statistically significant relationship between urinary ACE2 
and plasma insulin levels, Pearson correlations were calculated between these variables in the 
total groups of 17 week old mice after 10 weeks intervention with exercise and/or metformin. 
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Urinary ACE2 was significantly and negatively correlated with plasma insulin levels (Figure 37, 
r = -0.54, p<0.05).   
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5. DISCUSSION 
In our previous study, we reported that therapeutic intervention with the insulin sensitizer 
rosiglitazone, normalized hyperglycemia and improved renal damage by attenuating ACE2 
shedding. However, due to its potential side effects, this drug is no longer available in the 
market. Hence, in the current study, we investigated the effects of physical exercise training 
and/or metformin on glucose homeostasis and associated renal alterations in db/db type 2 
diabetic mice. Though several studies have shown the beneficiary effects of exercise with or 
without diet restriction on the primary disease diabetes (Knowler et al., 2002; Tuomilehto et al., 
2001; Pan et al., 1997; Fradkin et al., 2012), effects of these interventions on the complications 
associated with diabetes have not been extensively investigated. In addition, mechanisms 
underlying the positive effects of exercise on glucose homeostasis remain poorly understood. 
Both physical exercise and metformin are first-line interventions for the management of type 2 
diabetes. We thus investigated the effects of exercise training and/or metformin treatment on 
glucose homeostasis, albuminuria, renal ADAM17, ACE2 shedding, and renal pathology. In 
addition, we also focused on the effects of exercise and/or metformin on some of the plasma risk 
factors in diabetes. 
In our previous study using db/db mice, we showed that hyperglycemia is evident before the 
onset of hypertension and plays a pivotal role in triggering adverse effects (Senador et al., 2009), 
thus we speculate that lowering hyperglycemia is crucial in preventing long-term complications 
that might lead to end organ damage. In the current study, 6 week old db/db mice had 
significantly increased blood glucose levels compared to normal mice. At this early stage, db/db 
mice excreted higher levels of albumin and ACE2 in the urine, but no differences were observed 
in their total urinary protein excretion levels. Albuminuria is a widely accepted and well-
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established marker for diabetic nephropathy, which is considered as one of the major 
microvascular complications of diabetes that eventually manifests into ESRD (Jim et al., 2012). 
High blood glucose associated glomerular hyperfiltration and activated RAS are considered as 
primary causes underlying this implication (Kobori et al., 2007). Increased renal Ang II has been 
shown to cause depletion of glomerular nephrin, thus increasing the glomerular pore size 
(Giacchetti et al., 2005; Bichu et al., 2009). In addition, Ang II can enhance intraglomerular 
pressure by constricting both afferent and efferent arteriole, thus exhilarating albumin excretion 
into urine (Remuzzi & Bertani, 1998). However, onset of diabetes is difficult to ascertain and so 
many patients diagnosed with high blood glucose already have microalbuminuria (Lee, 2005). 
Moreover, recent clinical studies questioned the reliability of albuminuria in anticipating the 
progression and prevention of ESRD (de Galan et al., 2009). Alternatively, normal mice 
subjected to exercise training excreted significantly higher levels of urinary albumin with no 
differences in their blood glucose and renal morphologies. Therefore, there is a need for a more 
sensitive and specific marker for the better prediction of diabetic nephropathy.  
Increased ACE2 activity and protein in the urine of db/db diabetic mice is in close resemblance 
with diabetic patients (Xiao et al., 2012; Mizuiri et al., 2011), suggesting the syndrome of 
diabetic nephropathy in db/db mouse model reflects human diabetics with nephropathy. It has 
been suggested before that the origin of urinary ACE2 protein could be at least partly from the 
plasma or derived from the kidney (Lew et al., 2006), the organ where ACE2 is predominantly 
localized (Donoghue et al., 2000). However, as we reported earlier, there is no detectable ACE2 
activity in the plasma of normal non-diabetic and db/db mice (Chodavarapu et al., 2013); 
therefore we believe in the kidney as the source of urinary ACE2 in db/db mice, which is in 
agreement with recent findings in diabetic patients (Xiao et al., 2012). In fact, our results 
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demonstrated a strong association between urinary albumin and ACE2 suggesting ACE2 as a 
non-invasive biomarker for diabetic nephropathy. This observation was recently evaluated in 
type 2 diabetic human subjects (Park et al., 2013). It is presumed that albuminuria is an 
indication of glomerular damage (Ye et al., 2006) and urinary ACE2 is a reflection of tubular 
damage (Chodavarapu et al., 2013). Even though mechanisms responsible for urinary albumin 
and ACE2 are quite contrasting, we correlated urinary ACE2 with albuminuria to explore its 
potential use as a new, additional marker of renal injury.  
Physical exercise with or without metformin significantly lowered the blood glucose levels 
consistently and improved glucose tolerance of db/db mice. Blood glucose lowering effect of 
exercise was seen as early as 1 week after the initiation of treatment. In comparison, metformin 
treatment was effective lowering hyperglycemia in the early stages of diabetes, but failed with 
the progression of disease severity in late stages. Exercise mediated improvements in glucose 
homeostasis could at least be partially attributed to the elevated plasma insulin levels. Physical 
exercise training increased plasma insulin levels by almost three folds in db/db mice. Although 
type 2 diabetes is characterized by hyperinsulinemia, enhanced insulin levels may not be 
sufficient to overcome the tissue resistance to insulin. Based on our findings, we speculate that, 
further increase in the plasma insulin levels during exercise training could be able to counteract 
the resistance exhibited by various tissues and it could be one of the mechanisms behind 
improved glycemic control in exercised db/db mice. However, in contrast to our observation, a 
study conducted on type 2 diabetic subjects reported decreased blood glucose and plasma insulin 
levels with exercise (Musi et al., 2001), which could be explained by increased insulin 
sensitivity. Insulin sensitivity can be enhanced by changing the body composition (Yki-Jarvinen 
& Koivisto, 1983), stimulating muscle blood flow (Yki-Jarvinen & Koivisto, 1983) or GLUT-4 
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protein levels (Rodnick et al., 1990; Yki-Jarvinen & Koivisto, 1983). We noticed no differences 
in the body composition between exercised and sedentary diabetic and non-diabetic mice. 
However, we cannot rule out the possibility of enhanced insulin mediated GLUT-4 translocation 
from an intracellular pool to the plasma membrane of muscle and AMPK α2 activation in 
exercised diabetic mice (Scarpello & Howlett, 2008; Musi et al., 2002; Ivy, 1997; Musi et al., 
2001; Hughes et al., 1993). These improvements in exercised db/db mice were not associated 
with changes in body weight and composition. Since there are only very few studies that 
observed beneficial effects of physical activity alone without diet modifications (to lose weight) 
in diabetes, findings from our study highlight the notion that physical exercise alone can be 
effective in managing diabetes type 2. This, in turn, is supported by a randomized clinical trial 
conducted on individuals with impaired glucose tolerance (Pan et al., 1997). Physical exercise 
alone and in combination with metformin was consistently effective in attenuating albuminuria 
and proteinuria, reflecting its positive effects against diabetic nephropathy. This observation is in 
agreement with the previous reports (Kohzuki et al., 2001; Tufescu et al., 2008; Ishikawa et al., 
2012). However, exercise-induced albuminuria/proteinuria is often reported in normal as well as 
diabetic human subjects (Kornhauser et al., 2012; Koh et al., 2011; Heathcote et al., 2009), 
which could be attributed to the intensity and duration of exercise (Saeed et al., 2012). This is the 
reason why exercise should be well-controlled and some of the factors like maximal oxygen 
consumption (VO2), body composition, and sex should be considered while designing the 
exercise protocols. Indeed, exercise training attenuated ACE2 excretion in the urine of db/db 
mice. Since ACE2 is considered to be renoprotective, prevention of urinary ACE2 excretion, in 
addition to the improved albumin excretion rate, suggests the protective role of exercise in 
kidney damage. Improvements in albuminuria and ACE2 excretion were seen as early as 2 
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weeks after the initiation of treatment. To our knowledge, this is the first report showing that 
improved kidney function during exercise training is associated with a significant decrease in 
ACE2 excretion into urine. 
 Apart from its usage as a biomarker, a thorough urinalysis demonstrated that urinary ACE2 is 
enzymatically active and 20 kDa shorter. Since the kidney is the source of urinary ACE2; we 
speculated that 20 kDa shorter fragment of ACE2 in the urine of db/db mice is due to its 
ectodomain shedding from the kidney. ADAM17 protein that is implicated in the ectodomain 
shedding of ACE2 in vitro, was significantly increased in the kidney of db/db mice. In fact, our 
finding is in agreement with the recent report demonstrating increased renal ADAM17 protein 
expression in human subjects with renal disease (Melenhorst et al., 2009). Although it is reported 
that ADAM17 is predominantly localized to distal renal tubules (Lautrette et al., 2005), our 
results showed a strong staining in both proximal and distal cortical tubules and glomeruli but 
not in the medulla of db/db mice. This discrepancy may be due to differences in the species, age, 
or the severity of the disease. Further, immuno-double staining results demonstrated the co-
localization of ADAM17 and ACE2 proteins in the tubular cortex under diabetic conditions. In 
fact, the increased renal ADAM17 protein expression in db/db mice was significantly decreased 
by exercise training. This is the first study reporting effect of physical exercise training on 
ADAM17, a metalloproteinase that is implicated in many chronic diseases (Kaneko et al., 2011; 
White, 2003).  
In spite of some reports suggesting decreased ACE2 in diabetes (Reich et al., 2008; Tikellis et 
al., 2003), our previous studies showed a significant increase in renal ACE2 protein expression 
in db/db mice (Chodavarapu et al., 2013). In fact, plasma ACE activity and Ang II content were 
high in 8 week old db/db mice compared to normal mice (Senador et al., 2009) and this suggests 
91 
 
that the deleterious renal effects of Ang II is counterregulated by upregulating ACE2. As we 
reported earlier, renal ACE2 activity of 8 week old db/db mice is significantly higher than 31 
week old db/db mice. Based on these observations, we speculate that, with progression of the 
disease (age), the kidney is unable to maintain ACE2 levels due to escalating ADAM17 protein. 
As a consequence of increased renal ADAM17 protein and shedding of ACE2, db/db mice had a 
significantly increased glomerular surface area, glomerular and tubular basement membrane 
thickening, expanded mesangial matrix and collagen deposits. Strong staining for collagen was 
noticed in the interstitium, mesangial cells, and glomerular as well as tubular basement 
membranes, suggesting the involvement of both glomerular and tubular damage in the renal 
injury of db/db mice. In agreement with previous reports (Ghosh et al., 2009), physical exercise 
training blunted mesangial expansion and glomerular surface area of db/db mice. Reduced 
glomerular and tubular basement membrane thickening and attenuation of glomerular and 
tubular collagen deposits by exercise suggests that the beneficiary effect of exercise in renal 
injury is accompanied with the improvements in both glomerular and tubular pathologies in 
db/db mice. Since ACE2 is considered as renoprotective, ADAM17-induced shedding of ACE2 
is an important contributor to the pathogenesis of diabetic nephropathy. Basing on all these 
considerations, it is tempting to speculate that attenuation of ADAM17 by exercise training in 
the kidney is responsible for attenuating ACE2 shedding into urine of db/db diabetic mice and 
this could be considered as a renoprotective mechanism. In contrast, administration of metformin 
did not attenuate renal ADAM17 and ACE2 shedding and had no effect on the renal pathologies 
of diabetic mice. However, considering albuminuria and urinary ACE2 as risk markers of 
diabetic nephropathy, we might presume that metformin treatment could have beneficiary actions 
on diabetic renal pathologies during the initial stages. Unaltered levels in the expression and 
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activity of renal ACE2 between control, metformin-treated, and exercise-trained diabetic db/db 
mice needs further investigation. 
Continuing in this vein, we focused on the possible mechanisms that could be responsible for the 
upregulation of renal ADAM17 protein levels in db/db mice. Previously, it has been shown that 
several cell signaling pathways excitation results in dimeric to monomeric shift of ADAM17. 
This is associated with increased ADAM17 and decreased Timp3, suggesting Timp3 as an 
endogenous inhibitor of ADAM17 (Xu et al., 2012). Also, recent studies reported that deficiency 
of Timp3 results in increased ADAM17 activity, exacerbating diabetic nephropathy in Akita type 
1 diabetic mice (Basu et al., 2012). In contrast to these findings, we observed no differences in 
renal Timp3 protein levels among non-diabetic and diabetic db/db mice, highlighting the 
involvement of different mechanisms in the activation of ADAM17 in type 1 and type 2 diabetes. 
However, basing on the recent findings (Lautrette et al., 2005; Ford et al., 2013), hyperglycemia 
and activated Ang II could be possible reasons behind enhanced ADAM17 protein in the kidney 
of db/db mice.  
In addition to its positive effects on glucose homeostasis and renal pathologies, physical exercise 
training exerted beneficiary actions on metabolic abnormalities associated with type 2 diabetes. 
Plasma analysis showed db/db mice had significantly increased levels of plasma glucose, 
glucagon, and triglycerides and decreased levels of adiponectin. However, physical exercise 
training significantly attenuated plasma triglyceride levels of db/db mice. Previously, exercise 
training has been shown to improve renal function of chronic kidney disease patients by lowering 
plasma triglycerides, at least in partial (Toyama et al., 2010). Alternatively, metformin had no 
effect on the plasma glucose, glucagon, insulin or adiponectin. In fact, metformin treatment was 
associated with a significant increase in triglyceride levels of db/db mice, which in contrast, has 
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been shown to attenuate plasma triglyceride levels in rodent models as well as type 2 diabetic 
patients (Wulffele et al., 2004; Tessari & Tiengo, 2008). A combination of physical exercise 
training and metformin significantly decreased the plasma glucagon concentrations. 
Furthermore, we correlated these plasma risk factors with urinary ACE2 excretion to strengthen 
our notion of using urinary ACE2 as a surrogate marker for diabetes.  
Based on these results, it is tempting to speculate that physical exercise is capable of improving 
the complications of type 2 diabetes with minimal or no adverse side effects. Since exercise 
training has been shown to exert pronounced effects in type 2 diabetes and associated 
complications, physical training programs should be widely adopted into the medical care 
system. Though metformin treatment is also considered as a cost-effective intervention with 
minimal potential side effects in managing type 2 diabetes, our results demonstrate that it may be 
effective only during the initial stages of diabetes, or where the severity of the disease is less 
pronounced. This novel finding is in consensus with the recent report from DPP/DPPOS study 
demonstrating life style interventions were effective in reducing the incidence of diabetes by 
71% in human subjects with the age of 60 years, whereas administration of metformin exerted no 
effects. However, treatment with metformin had beneficial effects in participants 25 to 44 years 
old (Fradkin et al., 2012). 
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6. CONCLUSION 
Diabetic nephropathy is one of the major microvascular complications of diabetes that eventually 
manifests into ESRD. Ang II, a potent vasoconstrictor cleaved from Ang I, is responsible for 
renal damage in diabetes. ACE2 is highly expressed in the kidney and has been shown to be 
renoprotective by degrading Ang II to Ang-(1-7). Several studies demonstrated that 
pharmacological inhibition or deletion of ACE2 worsened albuminuria and glomerular sclerosis 
in diabetes. A Disintegrin and Metalloproteinases (ADAMs) were recently identified as an 
ectodomain sheddases of transmembrane proteins. ADAM17 mediated shedding of renal ACE2 
is an important contributor to the pathogenesis of diabetic nephropathy. 
In the current study, we demonstrated that 6 week old type 2 diabetic db/db mice developed 
hyperglycemia and excreted more amounts of urinary albumin and ACE2. Microalbuminuria is a 
widely accepted clinical sign of renal dysfunction in patients with diabetes. One of the aims of 
this study was to evaluate urinary ACE2 as a non-invasive biomarker for diabetic nephropathy. 
Urinary ACE2 was significantly and positively correlated with albuminuria, suggesting its 
potential to be an early biomarker. Indeed, renal ADAM17 and ACE2 protein levels were 
significantly enhanced in db/db mice. Increased ADAM17 and ACE2 proteins co-localized in the 
cortical tubules suggesting possible interaction in the diabetic kidney. Hence, in the present 
study, we hypothesized that lowering hyperglycemia would prevent or delay the progression of 
diabetic nephropathy by preventing renal ACE2 shedding mediated by ADAM17.  
Moderate intensity exercise training improved glucose homeostasis, attenuated albuminuria and 
ACE2 excretion as early as 2 week after the initiation of treatment. In addition, physical exercise 
decreased renal ADAM17 protein levels and ameliorated renal pathologies in trained db/db mice 
compared to control db/db mice. Interestingly, our results suggest that metformin was effective 
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in the initial stages of diabetes and had no effect in the later stages where the disease progress is 
more severe. Indeed, administration of metformin for 10 weeks had no effect on the albuminuria, 
renal ADAM17 protein, and shedding of ACE2. Further, our results demonstrated a significant 
association between blood glucose, urinary albumin, plasma insulin, glucagon, and triglycerides 
with urinary ACE2 excretion, suggesting urinary ACE2 as an alternate marker for diabetes. In 
addition, urinary ACE2 could be used as a screening tool in assessing the effectiveness of 
therapeutic interventions. Since exercise training has been shown to exert pronounced effects in 
type 2 diabetes and associated complications, with no compromising side effects, physical 
training programs should be widely adopted into the medical care system. 
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APPENDIX A  
 
Alteration of Renal Neprilysin, Angiotensin Converting Enzyme 2 (ACE2) and Nephrin in 
Streptozotocin (STZ) Diabetic Mice 
Hari K. Somineni, Nadja Grobe, Harshita Chodavarapu, Mariana Morris, Khalid M. Elased.  
      
Boonshoft School of Medicine, Wright State University, Dayton, OH  
 
Diabetic nephropathy is one of the major microvascular complications of diabetes which 
eventually manifests into end stage renal disease. Alteration in renin-angiotensin system (RAS) 
is considered to be the primary cause underlying this implication. Emerging evidence suggests 
that the biological actions of Ang II may be opposed by the formation of Ang (1-7), partly 
generated by the actions of ACE2 and neprilysin (NEP). NEP is a zinc-containing 
metallopeptidase catalyzing the conversion of Ang I to Ang-(1-7), a potent vasodilator, thus 
counteracting the deleterious effects of Ang II. In our previous studies it has been shown that 
renal NEP is down-regulated and ACE2 is up-regulated in type 2 diabetic (db/db) mice. The goal 
of the present study is to explore the role of renal NEP and ACE2 in the pathogenesis of diabetic 
nephropathy in the STZ mouse model of type 1 diabetes. Diabetes was induced by five 
consecutive injections of STZ (50 mg/kg, i.p.). Urine was collected in presence of protease 
inhibitor for measuring albumin, creatinine and total protein contents. STZ diabetic mice 
exhibited hyperglycemia, microalbuminuria and renal hypertrophy. Renal NEP activity, detected 
via formation of Ang-(1-7) (m/z 899), was significantly reduced by 30% in diabetic mice. Renal 
ACE2 activity, measured using the fluorogenic test assay, was found to be unaltered in diabetic 
and control mice. Western blot analysis demonstrated decreased renal NEP, nephrin and 
unaltered ACE2 protein expression in diabetic mice, which was further supported by 
immunohistochemical staining. In conclusion, decreased NEP coupled with depletion of nephrin 
in diabetes could possibly play a crucial role in the development of diabetic nephropathy. 
 
Poster presented in American Heart Association Meeting – High Blood Pressure Research 
(HBPR); Washington. D.C. 2012 
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APPENDIX B  
 
Upregulation of Tumor necrosis factor α-converting enzyme (TACE) Protein Expression in 
db/db Mice is reversed by Rosiglitazone 
Harshita Chodavarapu, Hari K. Somineni, Esam Salem, Mariana Morris, Khalid M. Elased.       
Boonshoft School of Medicine, Wright State University, Dayton, OH  
 
TACE, also known as ADAM17, is involved in the ectodomain shedding of several membrane 
bound proteins. Angiotensin converting enzyme 2 (ACE2), homologue of angiotensin converting 
enzyme (ACE), is known to be renoprotective by increasing the degradation of vasoactive 
peptide Angiotensin II (Ang II) to vasodilator peptide Ang-(1-7). It has been shown before that 
TACE mediates regulated ectodomain shedding of ACE2. PPARγ agonist, rosiglitazone, is 
known to impart renoprotection by attenuating albuminuria. However, the exact mechanism of 
renoprotection is not clear. Our previous results and others showed that renal ACE2 protein 
expression is increased during early stages of diabetes in db/db mice. We also demonstrated 
increased urinary ACE2 excretion in db/db mice. The goal of this study is to test the hypothesis 
that TACE is upregulated in db/db diabetic mice and treatment with rosiglitazone imparts 
renoprotection by attenuating the shedding of renal ACE2 via downregulating TACE protein 
expression. Male 6 week db/db mice were fed rosiglitazone (20mg/kg/day) for 10 weeks. 
Metabolic and urinary parameters were monitored weekly. Kidney lysate and urine was used to 
perform western blot and ACE2 activity (pmols/h/µg protein) respectively. db/db mice 
demonstrated glucose intolerance, hyperglycemia, and albuminuria at a very early age. 
Rosiglitazone treatment normalized blood glucose levels, improved glucose tolerance and 
decreased albuminuria in treated db/db mice. Western blot showed increased renal TACE protein 
expression of db/db mice compared to controls (p<0.05). Rosiglitazone treatment significantly 
decreased renal TACE protein expression in db/db mice compared to untreated mice (p<0.05). In 
addition, db/db mice demonstrated a 7 fold increase in urinary ACE2 activity compared to 
controls. Treatment with rosiglitazone significantly attenuated and normalized ACE2 activity in 
treated db/db mice. In conclusion, TACE is upregulated in db/db mice and normalizing 
hyperglycemia with rosiglitazone could impart renoprotection by decreasing renal TACE protein 
expression and shedding of renal ACE2.                                                                          
 
Poster presented in American Heart Association Meeting – High Blood Pressure Research 
(HBPR); Washington. D.C. 2012 
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APPENDIX C  
 
Insulin Normalizes Angiotensin Converting Enzyme 2 (ACE2) and Attenuates 
Albuminuria in Type 1 Diabetic Akita Mice 
Esam Salem, Hari K. Somineni, Harshita Chodavarapu, Mariana Morris, Khalid M. Elased.       
Boonshoft School of Medicine, Wright State University, Dayton, OH  
 
Diabetic nephropathy (DN) is a microvascular complication of diabetes that is clinically 
diagnosed by a progressive increase in albuminuria. Alterations within renin angiotensin system 
balance contribute to the pathogenesis of diabetic kidney disease. Angiotensin converting 
enzyme 2 (ACE2), a metallocarboxypetidase, has a renoprotective role due to its ability to form 
Angiotensin (1-7) [Ang-(1-7)] by degrading Angiotensin II (Ang II). Accumulating evidence 
shows that strict glycemic control attenuates diabetic kidney damage.  Therefore, the aim of this 
study is to test the hypothesis that normalizing hyperglycemia with insulin will reduce 
albuminuria by increasing ACE2 in Akita diabetic mice. Type 1 diabetic Akita mice and their 
wild type (WT) littermates were used. Metabolic parameters were monitored weekly. Urine was 
collected over 24 hours to measure urinary albumin, total protein and ACE2 activity. Akita mice 
developed significant hyperglycemia compared to WT mice. There was a significant increase in 
urinary albumin excretion in Akita mice compared to WT mice. In addition, Akita mice 
demonstrated a significant increase in renal and urinary ACE2 activity compared to WT mice 
(p<0.05). Western blot revealed upregulation of renal ACE2 and downregulation of renal ACE 
protein expression in Akita mice compared to WT mice. Treatment with insulin implants 
(LinβitR) for 20 weeks significantly decreased hyperglycemia in Akita mice. Insulin treatment 
significantly decreased urinary albumin excretion as well as renal and urinary ACE2 activity in 
Akita mice. Further, insulin administration, downregulated renal ACE2 and upregulated renal 
ACE protein expression in Akita mice. In conclusion, normalizing hyperglycemia in Akita mice 
with insulin decreased ACE2 protein expression and activity. 
                           
 
Poster presented in American Heart Association Meeting – High Blood Pressure Research 
(HBPR); Washington. D.C. 2012 
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APPENDIX D  
 
Alteration of Renal Neprilysin, Angiotensin Converting Enzyme 2 (ACE2) and Nephrin in 
Streptozotocin (STZ) Diabetic Mice 
Hari K. Somineni, Nadja Grobe, Harshita Chodavarapu, Mariana Morris, Khalid M. Elased.  
      
Boonshoft School of Medicine, Wright State University, Dayton, OH  
 
Diabetic nephropathy is one of the major microvascular complications of diabetes which 
eventually manifests into end stage renal disease. Alteration in renin-angiotensin system (RAS) 
is considered to be the primary cause underlying this implication. Emerging evidence suggests 
that the biological actions of Ang II may be opposed by the formation of Ang (1-7), partly 
generated by the actions of ACE2 and neprilysin (NEP). NEP is a zinc-containing 
metallopeptidase catalyzing the conversion of Ang I to Ang-(1-7), a potent vasodilator, thus 
counteracting the deleterious effects of Ang II. In our previous studies it has been shown that 
renal NEP is down-regulated and ACE2 is up-regulated in type 2 diabetic (db/db) mice. The goal 
of the present study is to explore the role of renal NEP and ACE2 in the pathogenesis of diabetic 
nephropathy in the STZ mouse model of type 1 diabetes. Diabetes was induced by five 
consecutive injections of STZ (50 mg/kg, i.p.). Urine was collected in presence of protease 
inhibitor for measuring albumin, creatinine and total protein contents. STZ diabetic mice 
exhibited hyperglycemia, microalbuminuria and renal hypertrophy. Renal NEP activity, detected 
via formation of Ang-(1-7) (m/z 899), was significantly reduced by 30% in diabetic mice. Renal 
ACE2 activity, measured using the fluorogenic test assay, was found to be unaltered in diabetic 
and control mice. Western blot analysis demonstrated decreased renal NEP, nephrin and 
unaltered ACE2 protein expression in diabetic mice, which was further supported by 
immunohistochemical staining. In conclusion, decreased NEP coupled with depletion of nephrin 
in diabetes could possibly play a crucial role in the development of diabetic nephropathy. 
 
Poster presented in Ohio Physiological Society Meeting (OPS); Dayton 2012 
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APPENDIX E  
 
Downregulation of Renal Neprilysin in Streptozotocin (STZ) Diabetic Mice 
Hari K. Somineni, Nadja Grobe, Khalid M. Elased.  
      
Boonshoft School of Medicine, Wright State University, Dayton, OH  
 
Diabetic nephropathy is one of the major microvascular complications of diabetes which 
eventually manifests into end stage renal disease. Alteration in renin-angiotensin system (RAS) 
is considered to be the primary cause underlying this implication. Emerging evidence suggests 
that the biological actions of Ang II may be opposed by the formation of Ang (1-7), partly 
generated by the actions of ACE2 and neprilysin (NEP). NEP is a zinc-containing 
metallopeptidase catalyzing the conversion of Ang I to Ang-(1-7), a potent vasodilator, thus 
counteracting the deleterious effects of Ang II. In our previous studies it has been shown that 
renal NEP is down-regulated and ACE2 is up-regulated in type 2 diabetic (db/db) mice. The goal 
of the present study is to explore the role of renal NEP and ACE2 in the pathogenesis of diabetic 
nephropathy in the STZ mouse model of type 1 diabetes. Diabetes was induced by five 
consecutive injections of STZ (50 mg/kg, i.p.). Urine was collected in presence of protease 
inhibitor for measuring albumin, creatinine and total protein contents. STZ diabetic mice 
exhibited hyperglycemia, microalbuminuria and renal hypertrophy. Renal NEP activity, detected 
via formation of Ang-(1-7) (m/z 899), was significantly reduced by 30% in diabetic mice. Renal 
ACE2 activity, measured using the fluorogenic test assay, was found to be unaltered in diabetic 
and control mice. Western blot analysis demonstrated decreased renal NEP, nephrin and 
unaltered ACE2 protein expression in diabetic mice, which was further supported by 
immunohistochemical staining. In conclusion, decreased NEP coupled with depletion of nephrin 
in diabetes could possibly play a crucial role in the development of diabetic nephropathy. 
 
Poster presented in Research Forum; WSU, OH 2012 
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APPENDIX F  
 
Behavioral Differences in Type II Diabetic Mice Treated with Exercise and Metformin 
 
Teresa L. Garrett, Emily Smith, Samantha Spitak, Torrey Cowan, Hari Somineni, Khalid 
Elased, Gregory Boivin and James B. Lucot.  
      
Boonshoft School of Medicine, Wright State University, Dayton, OH  
 
Diabetes and mental health disorders have a high co-morbidity of making their study a priority.  
Furthermore, the effects of standard therapeutics on these disorders are not well understood. 
Metformin (a biguanide) is the most commonly prescribed medication for type II diabetics. It 
treats insulin resistance primarily by controlling the amount of glucose in circulation.  In 
addition, exercise is commonly prescribed to diabetic patients in order to improve weight loss, 
and improve peripheral neuropathy. Exercise is also recommended for those with mental health 
disorders, most commonly depression and anxiety. Previous work in the lab using a leptin 
deficient mouse model (db/db) has demonstrated deficits in multiple behavioral tests.  The 
current experiment was completed to differentiate the effects of exercise and metformin on 
behavioral outcomes. 
 
 
Poster presented in Research Forum; WSU, OH 2012 
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APPENDIX G  
 
Physical Exercise Training and Metformin Treatment Attenuated Albuminuria and 
Shedding of ACE2 in db/db Mice 
 
Hari K. Somineni, Esam Salem, Gregory P. Boivin, Khalid M. Elased 
      
Boonshoft School of Medicine, Wright State University, Dayton, OH  
 
Angiotensin II (Ang II), a potent vasoconstrictor cleaved from Ang I, is responsible for the renal 
damage in diabetes. Studies have shown that the strict glycemic control and blockade of renin 
angiotensin system attenuates diabetic kidney damage. Angiotensin converting enzyme (ACE) 2 
is highly expressed in the kidney and has been shown to be renoprotective by degrading Ang II 
to Ang-(1-7). We have shown previously increased urinary ACE2 excretion in db/db type 2 
diabetic mice which contributes to the pathogenesis of diabetic nephropathy. We tested the 
hypothesis that physical exercise training and metformin treatment improve glucose homeostasis 
and attenuate albuminuria in db/db mice. We also investigated whether there is a correlation 
between urinary albumin excretion and shedding of ACE2 in diabetic mice. Six weeks old 
normal and db/db mice were subjected either to physical exercise training and/or metformin 
treatment (150 mg/kg/day) for 10 weeks. The exercise groups were run on a mouse forced 
exercise walking wheel system for 1 hour a day for 7 days a week at a speed of 8 m/min. 
Exercise training significantly lowered blood glucose, urinary albumin and ACE2 excretion 
(p<0.05) in db/db mice. Furthermore, exercise training lowered food and water intake of db/db 
mice, but had no effect on their body weights. Metformin treatment decreased hyperglycemia, 
urinary albumin and ACE2 excretion (p<0.05) only during the first 2 weeks of treatment. 
Further, urinary ACE2 correlated positively with, albuminuria (r=0.84; p<0.0001), glycemia 
(r=0.75; p<0.0001), plasma glucagon (r=0.66; p<0.001) and triglycerides (r=0.75; p<0.0001). In 
addition, exercise training reduced plasma triglycerides and enhanced insulin levels in db/db 
mice. In conclusion, physical exercise training attenuated microalbuminuria and shedding of 
renal ACE2 throughout the study. However, metformin was only effective during the initial 
stages of diabetes. 
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